



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 441 539 B1**

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
10.04.1996 Bulletin 1996/15

(21) Application number: 91300791.0

(22) Date of filing: 31.01.1991

(51) Int. Cl.⁶: **C07D 279/16**, C07D 279/14,
C07D 265/36, C07D 265/34,
C07D 417/04, C07D 417/06,
A61K 31/54, A61K 31/535

(54) Thiazine (or oxazine) derivatives and preparation thereof

Thiazin- (oder Oxazin)-Derivate und ihre Herstellung

Dérivés de thiazine (ou oxazine) et leur préparation

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(30) Priority: 08.02.1990 JP 31068/90
07.03.1990 JP 56220/90
09.03.1990 JP 59328/90

(43) Date of publication of application:
14.08.1991 Bulletin 1991/33

(73) Proprietor: TANABE SEIYAKU CO., LTD.
Chuo-ku Osaka (JP)

(72) Inventors:

- Ozeki, Masakatsu
Wako-shi, Saitama-ken (JP)
- Kodato, Shin-ichi
Kounosu-shi, Saitama-ken (JP)
- Yasuda, Kousuke
Kounosu-shi, Saitama-ken (JP)

- Kudo, Yukitsuka,
Sumire-so 103
Kyoto-shi, Kyoto-fu (JP)
- Maeda, Kayoko
Osaka-shi, Osaka-fu (JP)

(74) Representative: Hardisty, David Robert et al
BOULT, WADE & TENNANT
27 Farnival Street
London EC4A 3DF (GB)

(56) References cited:

EP-A- 0 116 368 FR-A- 2 332 756
GB-A- 1 173 942 US-A- 3 748 321

- PATENT ABSTRACTS OF JAPAN vol. 10, no. 13
(C-323)(2070)18 January 1986 & JP-A-60 166 674

Remarks:

The file contains technical information submitted
after the application was filed and not included in this
specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 441 539 B1

Description

This invention relates to novel thiazine (or oxazine) derivatives useful for the prophylaxis and treatment of ischemic encephalopathy and/or cerebral neurocyte dyscrasia, and processes for preparing the same.


Hemokinetic dyscrasia due to intracerebral hemorrhage or thromboembolism induces shortage of glucose and oxygen etc. which are source of energy for neurocytic activity and then induces nervous cellular necrosis at the ischemic lesion site. For treating such ischemic encephalopathy, there has hitherto been used a medicament such as flunarizine dihydrochloride which can increase cerebral blood flow and can promote supplement of glucose and oxygen etc. to the ischemic lesion site.

Besides, it has recently been clarified that calcium participates in cellular injury in ischemia and that the cellular injury in ischemia can be prevented by inhibiting the flow of calcium into neurocytes (cf. Trends in Pharmacological Science, 1989, 10, 397). Thus, it has been desired very much to develop a calcium antagonistic agent which can directly act on the cerebral cells.

An object of this invention is to provide novel compounds which have excellent calcium antagonistic activity within the cerebral tissues and are useful for the prophylaxis and treatment of ischemic encephalopathy and/or cerebral neurocyte dyscrasia.

EP-A-116 368 discloses compounds for the treatment of cardiovascular disease, and FR-A-2 332 756 discloses compounds for the treatment of inflammatory disease; compounds disclosed in both these prior art specifications have structures which are closely related to the compounds of the present invention. However, neither of these prior art specifications are considered to have relevance to the provision of compounds which possess central Ca^{++} antagonistic activity and/or Ca^{++} antagonistic activity in cerebral blood vessels.

The compounds of this invention are thiazine or oxazine derivative of the following formula [I]:



wherein R^1 and R^2 are both hydrogen atom or form a naphthalene ring together with the benzene ring; R^3 and R^4 are both hydrogen atom, or one of them is a halogen atom and another is hydrogen atom; X is sulfur atom or oxygen atom; R^5 and R^6 are the same or different and are each i) hydrogen atom, ii) a lower alkyl, iii) a cycloalkyl, iv) a substituted phenyl, v) naphthyl, vi) a lower alkyl which is substituted by a substituted or unsubstituted phenyl, or vii) a sulfur-containing monoheterocyclic group; one of Z^1 and Z^2 is oxygen atom and another is two hydrogen atoms; A is a lower alkylene; R^7 and R^8 are the same or different and are each i) hydrogen atom, ii) a lower alkyl, iii) a lower alkenyl, iv) a lower alkynyl, or v) a lower alkyl which is substituted by a substituted or unsubstituted phenyl, or both form together with the adjacent nitrogen atom a nitrogen-containing monoheterocyclic group; provided that when both of R^1 and R^2 are hydrogen atom, Z^2 is oxygen atom and either one of R^5 and R^6 is a substituted phenyl, naphthyl or a sulfur-containing monoheterocyclic group, or a pharmaceutically acceptable salt thereof.


In the compounds of the formula [I], the lower alkyl, lower alkylene and lower alkoxy denotes an alkyl, alkylene and alkoxy group having 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms. The lower alkenyl and alkynyl denotes an alkenyl or alkynyl group having 2 to 6 carbon atoms, preferably 2 to 4 carbon atoms. The cycloalkyl denotes a cycloalkyl group having 3 to 8 carbon atoms, preferably 5 to 6 carbon atoms. The sulfur-containing monoheterocyclic group includes, for example, thienyl group, and the substituted phenyl includes a phenyl group which is substituted by one or two substituents selected from a halogen atom, a trihalogeno(lower)alkyl, a lower alkyl and a lower alkoxy, for example, a halogenophenyl, a dihalogenophenyl, a trihalogeno(lower)alkylphenyl, a lower alkylphenyl, a lower alkoxyphenyl, or di(lower alkoxy)phenyl. The nitrogen-containing monoheterocyclic group includes, for example, imidazolyl, morpholinyl, pyrrolidinyl, piperidinyl, and piperazinyl.

Preferred compounds are compounds of the formula [I] wherein R^3 and R^4 are both hydrogen atom; one of R^5 and R^6 is hydrogen atom and another is a halogenophenyl, a trihalogeno(lower)alkylphenyl; A is methylene or ethylene; X is sulfur atom; R^7 and R^8 are the same or different and are each a lower alkyl.

The compounds [I] of this invention can be prepared by the following processes.

(a) Process A


The compounds [I] may be prepared by reacting a compound of the formula:




wherein R¹, R², R³, R⁴, R⁵, R⁶, X and Z¹ are as defined above, or a salt thereof with a compound of the formula:



wherein Y¹ and Y² are the same or different and are each a reactive residue, and A and Z² are as defined above, to give a compound of the formula:




wherein R¹, R², R³, R⁴, R⁵, R⁶, X, A, Z¹, Z², and Y¹ are as defined above, and then reacting the above compound [IV] with an amine compound of the formula:



wherein R⁷ and R⁸ are as defined above, or a salt thereof.

(b) Process B

45 The compounds [I] may be prepared by reacting the compound of the formula [II] or a salt thereof with a compound of the formula:



wherein Y³ is a reactive residue, and Z², A, R⁷ and R⁸ are as defined above.


55 (c) Process C

The compounds [I] wherein A is ethylene, Z¹ is two hydrogen atom, and Z² is oxygen atom may be prepared by reacting the compound of the formula [II] or a salt thereof with an acrylic acid compound of the formula:



[VII]


wherein Y^2 is as defined above, to give a compound of the formula:



wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , and X are as defined above, and then reacting the above compound [VIII] with an amine compound [V].

(d) Process D

The compounds [I] wherein at least one of R^7 and R^8 is a lower alkyl, a lower alkenyl, a lower alkynyl, or a lower alkyl which is substituted by a substituted or unsubstituted phenyl may be prepared by reacting a compound of the formula:



wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , X , A , Z^1 , and Z^2 are as defined above, and R^{71} is hydrogen atom, a lower alkyl, a lower alkenyl, a lower alkynyl, or a lower alkyl which is substituted by a substituted or unsubstituted phenyl, or a salt thereof with a compound of the formula:



[IX]

wherein R^{81} is a lower alkyl, a lower alkenyl, a lower alkynyl, or a lower alkyl which is substituted by a substituted or unsubstituted phenyl, and Y^4 is a reactive residue.

In the above reactions, the starting compounds of the formulae [II], [V] and [VI] and the compounds of the formula [I-a] may be used in a free form or in the form of a conventional acid addition salt such as mineral acid salts or organic acid salts. The reactive residues Y^1 , Y^2 , Y^3 and Y^4 includes, for example, a halogen atom (e.g. chlorine atom, bromine atom, etc.), a lower alkylsulfonyloxy, or a lower alkylphenylsulfonyloxy.

The condensation reaction between the compound [II] and the compound [III], the compound [VI], or the acrylic acid compound [VII], and the condensation reaction between the compound [I-a] and the compound [IX] can be carried out in an appropriate solvent in the presence of a base. These reactions proceed at a temperature of from cooling temperature to elevated temperature, preferably 0° to 100°C .

The reaction between the compound [IV] or the compound [VIII] and the amine compound [V] can be carried out in the presence or absence of a base in an appropriate solvent or without solvent. This reaction proceeds at a temperature of from cooling temperature to elevated temperature, preferably 0° to 100°C .

The base used in the above reactions includes any conventional bases, preferably tri(lower alkyl)amines, N-lower alkylmorpholines, N,N-di(lower alkyl)anilines, pyridine, alkali metal hydrogen carbonates, alkali metal carbonates, and the like.

The solvent used in the above reactions includes any conventional inert solvents, preferably acetone, toluene, tetrahydrofuran, dioxan, methylene chloride, chloroform, dimethylformamide, dimethyl sulfoxide, methanol, ethanol, and the like.

In case of Z¹ being two hydrogen atoms, the above reaction proceeds without racemization, and hence, when an optically active starting compound wherein Z¹ is two hydrogen atoms is used, there can be obtained an optically active compound [I].

Besides, the compounds [I] can optionally be subjected to optical resolution to give each optically active compounds [I]. The resolving agent may be any conventional resolving agents and further includes an optically active 3-[(5-chloro-2-nitrophenyl)thio]-2-hydroxy-3-(4-methoxyphenyl)propionic acid. For instance, an optically active compound [I] can be obtained by reacting a racemic compound [I] with a resolving agent to form a diastereomer salt, dividing the salt into each isomer by the difference of solubility in a solvent, followed by treating with a basic substance.

The desired compounds [I] of this invention may be used in a free form or in the form of a pharmaceutically acceptable salt. The pharmaceutically acceptable salt includes inorganic acid salts (e.g. hydrochloride, hydrobromide, sulfate, etc.), or organic acid addition salts (e.g. oxalate, fumarate, maleate, etc.).


The compounds [I] of this invention include also the optical isomers owing to the asymmetric carbon at 2-position of the thiazine or oxazine ring and also a mixture of the isomers.

The compounds [I] or pharmaceutically acceptable salts thereof of this invention can be administered orally or parenterally to a warm-blooded animal, including human being, and can be used in a conventional pharmaceutical preparation, such as tablets, granules, capsules, powders, injections, and the like.

The dosage of the compounds [I] or pharmaceutically acceptable salts thereof of this invention may vary depending on the administration route, age, weight and state of patient, severity of diseases, and the like, but is usually in a range of about 0.1 to 100 mg/kg per day, preferably about 3 to 30 mg/kg per day.

The starting compounds [II] include novel compounds of the formula:

25




30

wherein X' is sulfur atom or oxygen atom; R⁵¹ and R⁶¹ are the same or different and are each i) hydrogen atom, ii) a lower alkyl, iii) a cycloalkyl, iv) a substituted phenyl, v) naphthyl, vi) a lower alkyl which is substituted by a substituted or unsubstituted phenyl, or vii) a sulfur-containing monoheterocyclic group; Z¹¹ is oxygen atom or two hydrogen atoms; provided that when Z¹¹ is two hydrogen atoms and R⁵¹ and R⁶¹ are both hydrogen atom, X' is sulfur atom, which can be prepared by the following processes.

35

The compounds [II-a] wherein Z¹¹ is oxygen atom can be prepared by reacting a compound of the formula:


40



45


wherein X' is as defined above, with a compound of the formula:

50




55

wherein Y⁵ is a halogen atom, Y⁶ is a halogen atom or a lower alkoxy, and R⁵¹ and R⁶¹ are as defined above, in the presence or absence of a base (e.g. sodium acetate, potassium hydroxide, etc.), and when a compound of the formula:



wherein R⁵¹, R⁶¹, X', and Y⁵ are as defined above, is obtained, and the above compound [XII] is further subjected to a ring-closing reaction in the presence of a base (e.g. potassium carbonate, etc.).

15 The compounds [II-a] wherein Z¹¹ is oxygen atom, and one of R⁵¹ and R⁶¹ is hydrogen atom and other is a substituted phenyl, naphthyl, a lower alkyl which is substituted by a substituted or unsubstituted phenyl or a sulfur-containing monoheterocyclic group can be prepared by halogenating a compound of the formula:



wherein X' is as defined above, then reacting the resulting 3-halogenated compound with a compound selected from a substituted benzene, naphthalene and a sulfur-containing monoheterocyclic compound in the presence of a Lewis acid (e.g. stannic chloride, etc.), or reacting the compound [XIII] with a substituted or unsubstituted benzaldehyde compound in the presence of a base (e.g. sodium methoxide, etc.), followed by subjecting to catalytic reduction with a catalyst (e.g. palladium on charcoal, etc.).

Besides, the compounds [II-a] wherein Z¹¹ is two hydrogen atoms can be prepared by reducing the corresponding compounds [II-a] wherein Z¹¹ is oxygen atom in the presence of a reducing agent (e.g. alkali metal borohydride, diborane, etc.).

Another starting compounds [II] can also be prepared from a corresponding substituted or unsubstituted 2-amino(thio)phenol or a corresponding substituted or unsubstituted 1-amino-2-naphthol (or naphthalenethiol) in accordance with the procedure disclosed above.

The activities of the compounds of this invention were tested.

Experiment 1

Activity against entrance of calcium into cerebral synaptosome:

A cerebral synaptosome suspension was prepared from the cerebral cortex of rat in accordance with the procedure disclosed in The Journal of Physiology, 1989, 387, pages 415-423. To the suspension were added a fluorescent reagent (cf. "Note" hereinbelow) and a solution of test drug, and thereto was further added potassium chloride to depolarize. The fluorescent strength of the mixture was measured at 500 nm when irradiating mutually UV rays of wavelength of 340 nm and 380 nm with an apparatus for measuring intracellular calcium (CAF-100, manufactured by Nippon Bunko K.K.). The activity of the test drug for inhibiting the entrance of calcium into the synaptosome was calculated based on the rate of specific change (ΔR) of fluorescent strength at peak by the following equation. As a control, dimethylsulfoxide was used instead of the test drug.

$$\left[1 - \frac{\text{Average } [\Delta R] \text{ in medicated group}}{\text{Average } [\Delta R] \text{ in control group}} \right] \times 100$$

wherein R = fluorescent strength at 340 nm/fluorescent strength at 380 nm.

[Note]: The fluorescent reagent = 1-(2-(5'-carboxyoxazol-2'-yl)-6-aminobenzofuran-5-oxo)-2-(2'-amino-5'-methylphenoxy)ethane-N,N,N',N'-tetraacetic acid pentaacetoxymethyl ester (trade name, Fura 2-MA, manufactured by Dojin Kenkyusho).

Results

When the compounds as shown in the following Table 1 were used as the test drug in a concentration of 10^{-5} M, these compounds showed the inhibitory activity of calcium entrance as shown in Table 1.

















Table 1

Test compound:

No.	R ¹	R ²	R ⁵	Z ¹	Z ²	A	-NR ⁷ R ⁸	Inhibitory rate of calcium entrance (%)
1				H ₂	O	-CH ₂ -	-N< CH ₃ CH ₃	69.8
2				H ₂	O	-CH ₂ -	-N< C ₂ H ₅ C ₂ H ₅	54.2
3				O	H ₂	-CH ₂ CH ₂ -	-N< CH ₃ CH ₃	59.6
4				O	H ₂	-CH ₂ CH ₂ -	-N< CH ₃ CH ₂ CH=CH ₂	67.0
5	H	H		H ₂	O	-CH ₂ -	-N< CH ₃ CH ₂ CH ₂ -	70.1
6				H ₂	O	-CH ₂ -	-N< 	55.6

- to be continued -

Table 1 (Continue)

No.	Test compound:				Z ²	A	-NR ⁷ R ⁸	Inhibitory rate of calcium entrance (%)
	R ¹	R ²	R ⁵	Z ¹				
7				H ₂	O	-CH ₂ -		54.2
8				H ₂	O	-CH ₂ -		56.2
9				O	H ₂	-CH ₂ CH ₂ -		51.8
10				O	H ₂	-CH ₂ CH ₂ -		53.4

Experiment 2

Activity for protecting cerebral anoxia induced by potassium cyanide:
















The test drug was orally administered to mice. One hour after the administration, potassium cyanide (2.4 mg/kg) was administered into the tail vein, and the survival time (second) of the mice was measured. On the basis of the average survival time in the medicated group and the control group, the rate of prolonging of the survival time was calculated by the following equation. In the control group, distilled water was administered instead of the test drug.

$$\left[\frac{\text{Average survival time in medicated group}}{\text{Average survival time in control group}} - 1 \right] \times 100$$

Results

When the compounds as shown in the following Table 2 were orally administered as the test drug in a dose of 10 mg/kg, these compounds showed the prolonging rate of survival time as shown in Table 2A.

Table 2A

Test compound:										Prolonging rate of survival time (%)								
										No.	R ¹	R ²	R ⁵	Z ¹	Z ²	A	R ⁷	R ⁸
1	H	H		-Cl	H ₂	O	-CH ₂ -	-C ₂ H ₅	-C ₂ H ₅	62								
2				-Cl	H ₂	O	-CH ₂ -	-CH ₃	-CH ₃	49								
3				-Cl	H ₂	O	-CH ₂ -	-C ₂ H ₅	-C ₂ H ₅	65								
4				-F	O	H ₂	-CH ₂ -	-CH ₃	-CH ₃	62								
5				-F	O	H ₂	-CH ₂ CH ₂ -	-CH ₃	-CH ₃	56								
6	H	H			H ₂	O	-CH ₂ -	-C ₂ H ₅	-C ₂ H ₅	48								

The compounds (I) of this invention can inhibit the calcium entrance into the cerebral synaptosome and show excellent central calcium antagonistic activity and/or excellent calcium antagonistic activity in cerebral blood vessel, and can be used for the treatment and prophylaxis of cerebral diseases due to cerebral blood flow disorder at acute and chronic periods, for example, subarachnoid hemorrhag, cerebral infarction, etc. The compounds (I) of this invention have also

an activity for protecting cerebral neurocyte. For example, when 2-(4-chlorophenyl)-4-(diethylamino)acetyl-3,4-dihydro-2H-1,4-benzothiazine was intraperitoneally administered to evanescent cerebral ischemic rats with ligating four vessels in a dose of 1.5 mg/kg twice a day for four days, it increased the number of normal pyramidal cells at hippocampus CA₁ region in about 90 % in comparison with the non-medicated group. Accordingly, the compounds (I) of this invention can effectively be used for the prophylaxis, treatment and amelioration of sequelae of cerebral neurocyte dyscrasia, for example, disturbances of consciousness (e.g. somnolenz, sopor, coma, stupor, clouding of consciousness, etc.), motor paralysis (e.g. parkinsonism, etc.), cerebral neuropathy (e.g. dysuria, etc.), speech and language disorders (e.g. articulation disorders, aphasia, semantic aphasia, etc.), sensitive disorders (e.g. pain, sysesthesia, heat sensibility disorder, etc.), psychological disorders (e.g. dementia, hallucination, delusion, delirium, poriomania, melancholia, neurosis, emotional incontinence, etc.), and the like, and further the prophylaxis of palindromia and also the prophylaxis of exacerbation and progression of the symptoms. Moreover, the compounds (I) of this invention show little activity to heart and circular organs and hence has characteristics of direct action onto the cerebral cells. In addition, the compounds (I) of this invention have low toxicity and has high safety. For example, when the compounds of this invention such as 2-(4-chlorophenyl)-4-(diethylamino)acetyl-3,4-dihydro-2H-1,4-benzothiazine oxalate, 3-(4-chlorophenyl)-1-(diethylamino)acetyl-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine oxalate, and 1-[3-(dimethylamino)propyl]-3-(3-trifluoromethylphenyl)-1H-naphtho[2,1-b][1,4]thiazin-2[3H]-one oxalate were orally administered to mice in a dose of 500 mg/kg, no mouse died even after 7 days.

The compounds of this invention are illustrated by the following Examples but should not be construed to be limited thereto.

Example 1

(1) To a mixture of 2-(4-fluorophenyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine (4.0 g), sodium borohydride (2.91 g) and tetrahydrofuran (100 ml) is added dropwise with stirring boron trifluoride etherate complex (12.5 ml) at room temperature, and the mixture is refluxed for 1.5 hour. After cooling, to the mixture is added dropwise 10 % hydrochloric acid (35 ml), and the mixture is further refluxed for one hour. The reaction mixture is poured into ice water and made alkaline with potassium carbonate and extracted with ethyl acetate. The ethyl acetate layer is washed, dried and distilled to remove the solvent. The residue is recrystallized from isopropyl ether to give 2-(4-fluorophenyl)-3,4-dihydro-2H-1,4-benzothiazine (3.45 g, yield 91 %) as crystals.

M.p. 134 - 135.5°C.

(2) To a solution of the compound obtained above (2.60 g) and triethylamine (3.6 ml) in methylene chloride (45 ml) is added dropwise a solution of chloroacetyl chloride (1.70 ml) in methylene chloride (5 ml) under ice cooling, and the mixture is stirred at room temperature for one hour. After the solvent is distilled off, to the residue are added ethyl acetate and water, and the ethyl acetate layer is washed with water, dried and distilled to remove the solvent. The residue is recrystallized from isopropyl ether to give 4-chloroacetyl-2-(4-fluorophenyl)-3,4-dihydro-2H-1,4-benzothiazine (3.02 g, yield 89 %).

M.p. 122 - 123.5°C.

(3) To a solution of the compound obtained above (1.20 g) in tetrahydrofuran (15 ml) is added a 15 % solution of dimethylamine in methanol (15 ml), and the mixture is stirred at room temperature for 20 hours. The solvent is distilled off, and to the residue are added ethyl acetate and aqueous sodium hydrogen carbonate solution. The ethyl acetate layer is washed, dried, and distilled to remove the solvent. The residue is dissolved in ethanol-ether and thereto is added one equivalent of oxalic acid. The resulting precipitate is recrystallized from ethanol-ether to give 4-(dimethylamino)acetyl-2-(4-fluorophenyl)-3,4-dihydro-2H-1,4-benzothiazine oxalate (1.45 g, yield 93 %).

M.p. 171.5 - 172.5°C.

Examples 2 to 17

(1) The corresponding starting materials are treated in the same manner as described in Example 1-(1) to give the compounds as shown in Tables 3 and 4.

Table 3








Compd. symbol				
	R ²	R ³	X	M.p. (solvent for recrystal.)
A	H	Cl	S	139 - 142°C (isopropyl ether)
B	H	H	O	99 - 100°C (isopropyl ether-n-hexane)

Table 4

Compd. symbol		
	R ⁵	M.p. (solvent for recrystal.) etc.
C		74 - 75°C (n-hexane)
D		101.5 - 103°C (isopropyl ether-n-hexane)
E		84 - 89°C (ethyl acetate-n-hexane)
F		93 - 95°C (ethyl acetate-n-hexane)
G		110 - 112°C (ethyl acetate-n-hexane)

(2) The compounds obtained in the above (1) or corresponding compounds are reacted with chloroacetyl chloride in the same manner as described in Example 1-(2) to give the compounds as shown in Tables 5 and 6.

Table 5










Compd. symbol				
	R ²	R ³	X	M.p. (solvent for recrystal.) etc.
A	H	Cl	S	119.5 - 121°C (ethyl acetate-n-hexane)
B	H	H	O	caramel, MS (m/z): 321 (M ⁺), IR $\nu_{\text{max}}^{\text{Neat}}$ (cm ⁻¹): 1670

Table 6

Compd. symbol		
	R ⁵	M.p. (solvent for recrystal.) etc.
C		104 - 105.5°C (ethyl acetate-n-hexane)
D		133 - 135.5°C (ethanol)
E		93 - 97°C (ethanol)
F		caramel, MS (m/z): 371 (M ⁺), IR $\nu_{\text{max}}^{\text{CHCl}_3}$ (cm ⁻¹): 1670
G		121 - 123°C (isopropyl ether)

- to be continued -

Table 6 (Continue)

Compd. symbol	R ⁵	M.p. (solvent for recrystal.) etc.
H		94 - 95°C (ethanol)
I		110 - 112°C (ether)

(3) The compounds of the above (2) or the compound in Example 1-(2) are reacted with the corresponding amine compound in the same manner as described in Example 1-(3) to give the compounds as shown in Tables 7 to 9.

Table 7


Ex. No.			
	R ²	R ³	M.p. (solvent for recrystal.)
2	H	Cl	Oxalate: 162 - 163.5°C (ethanol-ether)

Table 8
















Ex. No.			
	R ⁵		M.p. (solvent for recrystal.) etc.
3		N(C ₂ H ₅) ₂	65-68°C (isopropyl ether-n-hexane) oxalate: 143-144°C (dec.) (methanol-ether)
4		N(C ₂ H ₅) ₂	oxalate: 180-182°C (ethanol)
5		N(C ₂ H ₅) ₂	oxalate: 111-113°C (dec.) (ethanol-ether)
6		N(C ₂ H ₅) ₂	oxalate: 146-148°C (dec.) (ethanol-ether)
7		N(C ₂ H ₅) ₂	oxalate: 166.5-167.5°C (dec.) (ethanol-ether)
8		N(CH ₃) ₂	oxalate: 192-194°C (dec.) (ethanol-ether)
9		N(C ₂ H ₅) ₂	oxalate: 177-179°C (ethanol-ether)
10		N(C ₂ H ₅) ₂	oxalate: 161-163°C (ethanol-ether)

Table 9

Ex. No.			
	X		M.p. (solvent for recrystal.) etc.
11	S	N(CH ₃) ₂	hydrochloride: 253.5-255.5°C (dec.) (ethanol- ether)
12	S		oxalate: 177-179°C (dec.) (ethanol-ether)
13	S		oxalate: 197.5-198.5°C (dec.) (methanol)
14	O	N(CH ₃) ₂	oxalate: 211-213°C (dec.) (methanol-ether)
15	O	N(C ₂ H ₅) ₂	oxalate: 144-146°C (dec.) (ethanol-ether)
16	S	NHCH ₃	oxalate: 225-227°C (dec.) (methanol)
17	S		oxalate: powder MS (m/z): 498, 496 (M ⁺), 345 IR _{max} ^{Nujol} (cm ⁻¹): 1720, 1670

Example 18

(1) To a mixture of 2-(4-chlorophenyl)-3,4-dihydro-2H-1,4-benzothiazine (9.62 g), sodium hydrogen carbonate (6.0 g), methylene chloride (100 ml) and water (50 ml) is added dropwise with stirring a solution of acryloyl chloride (5.0 g) in methylene chloride (20 ml) under ice cooling over a period of about 30 minutes. The mixture is stirred at room temperature for 3 hours, and the organic layer is washed and dried. After the solvent is distilled off, the resulting crystals are washed with n-hexane to give 2-(4-chlorophenyl)-4-acryloyl-3,4-dihydro-2H-1,4-benzothiazine (10.76 g, yield 93 %).

M.p. 122 - 124°C.



(2) To a suspension of the compound obtained above (2.21 g) in ethanol (50 ml) is added a 31 % solution of dimethylamine in ethanol (20 ml), and the mixture is stirred at room temperature for one hour. The solvent is distilled off, and to the residue is added hydrogen chloride-ethanol. Ethanol is distilled off, and the residue is recrystallized from ethanol-ether to give 2-(4-chlorophenyl)-4-[3-(dimethylamino)propionyl]-3,4-dihydro-2H-1,4-benzothiazine hydro-

chloride (2.13 g, yield 77 %).
M.p. 188 - 190°C.

Example 19

The corresponding starting material is treated in the same manner as described in Example 18-(2) to give the compound as shown in Table 10.

Table 10

Ex. No.		
		M.p. (solvent for recrystal.)
19	N(C ₂ H ₅) ₂	hydrochloride: 191-194°C (ethanol-ether)

Example 20

To a solution of 2-(4-chlorophenyl)-3,4-dihydro-2H-1,4-benzothiazine (0.52 g) and N,N-dimethylaniline (0.97 g) in methylene chloride (15 ml) is added dimethylaminoacetyl chloride hydrochloride (0.63 g) under ice cooling, and the mixture is stirred at the same temperature for 2.5 hours. To the reaction mixture is added aqueous sodium hydrogen carbonate solution, and is extracted with chloroform. The chloroform layer is washed, dried and distilled to remove the solvent. The residue is treated with hydrochloric acid and the resulting salt is recrystallized from ethanol-ether to give 2-(4-chlorophenyl)-4-(dimethylamino)acetyl-3,4-dihydro-2H-1,4-benzothiazine hydrochloride (0.63 g, yield 86 %).
M.p. 253 - 255°C. (dec.)

Example 21

A mixture of 2-(4-chlorophenyl)-4-(N-methylaminoacetyl)-3,4-dihydro-2H-1,4-benzothiazine (1.80 g), allyl bromide (0.52 ml), potassium carbonate (2.25 g) and dimethylformamide (20 ml) is stirred at room temperature for 3.5 hours. The reaction mixture is poured into water, and the mixture is extracted with ethyl acetate. After the solvent is distilled off, the residue is purified by silica gel column chromatography (solvent, chloroform : methanol = 40 : 1). The caramel thus obtained is dissolved in ether and thereto is added 1.1 equivalent of oxalic acid. The resulting precipitate is washed with ether and dried to give 4-(N-allyl-N-methylaminoacetyl)-2-(4-chlorophenyl)-3,4-dihydro-2H-1,4-benzothiazine oxalate as powder.

Mass (m/z): 374, 372 (M⁺)

IR $\nu_{\text{max}}^{\text{Nujol}}$ (cm⁻¹): 1720, 1680

Example 22

2-(4-Chlorophenyl)-4-(N-methylaminoacetyl)-3,4-dihydro-2H-1,4-benzothiazine and 2-propynyl bromide are treated in the same manner as described in Example 21 to give 4-[N-(2-propynyl)-N-methylaminoacetyl]-2-(4-chlorophenyl)-3,4-dihydro-2H-1,4-benzothiazine oxalate.

M.p. 169.5 - 171°C (dec.) (recrystallized from ethanol-ether).

Example 23

(1) To a mixture of 2-(4-chlorophenyl)-3,4-dihydro-2H-1,4-benzothiazine (1.08 g), ethyl acetate (20 ml) and aqueous sodium hydrogen carbonate solution (20 ml) is added dropwise a solution of 4-bromobutyryl chloride (0.97 g) in ethyl acetate (5 ml) with stirring under ice cooling. The ethyl acetate layer is washed, dried and distilled to remove the solvent. The residue is recrystallized from ethyl acetate-n-hexane to give 4-(4-bromobutyryl)-2-(4-chlorophenyl)-3,4-dihydro-2H-1,4-benzothiazine (1.58 g, yield 93 %).

M.p. 91 - 92°C.

(2) To a solution of the compound obtained above (1.19 g) in tetrahydrofuran (5 ml) is added a 20 % solution of dimethylamine in tetrahydrofuran (5 ml), and the mixture is stirred at room temperature for 5 hours. After the reaction is completed, the solvent is distilled off, and to the residue are added ethyl acetate and aqueous sodium hydrogen carbonate solution. The ethyl acetate layer is washed, dried, and distilled to remove the solvent. The oily residue is dissolved in ethanol and thereto is added oxalic acid (0.22 g). The resulting precipitate is recrystallized from ethanol-ether to give 2-(4-chlorophenyl)-4-[4-(dimethylamino)butanoyl]-3,4-dihydro-2H-1,4-benzothiazine oxalate (1.03 g, yield 76 %).

M.p. 170 - 170.5°C. (dec.)

Example 24






To a solution of 1-amino-2-naphthalenethiol (27.81 g) in ethanol (500 ml) is added sodium borohydride (11.35 g) at room temperature. The mixture is stirred for 20 minutes, and thereto is added dropwise acetic acid (200 ml) and is further added sodium acetate (24.6 g). To the mixture is further added dropwise methyl α -bromo-4-chlorophenylacetate (46.8 g), and the mixture is stirred at room temperature under argon overnight. The reaction mixture is poured into ice water and the resulting precipitate is separated by filtration, washed, dried and recrystallized from tetrahydrofuran-n-hexane to give 3-(4-chlorophenyl)-1H-naphtho-[2,1-b][1,4]thiazin-2(3H)-one (44.45 g, yield 82.6 %) as crystals.

M.p. 235.5 - 237.5°C.

Examples 25 to 31

The corresponding starting materials are treated in the same manner as described in Example 24 to give the compounds as shown in Table 11.

Table 11

Ex. No.			
	R ⁵	R ⁶	M.p. (°C)
25A	H	H	200 - 201°C *1
25B	CH ₃	CH ₃	182 - 183°C *2
26	H		192 - 194°C *1
27	H		250 - 252.5°C *1
28	H		244 - 246°C *1
29	H		251 - 253°C *1

- to be continued -

Table 11 (Continue)

Ex. No.			
	R ⁵	R ⁶	M.p. (°C)
30	H		203.5 - 206°C *1
31	H		233 - 235°C *1

*1) Recrystallized from tetrahydrofuran-hexane

*2) Recrystallized from tetrahydrofuran-isopropyl ether

Example 32

To a mixture of 1-amino-2-naphthol (9.4 g), N,N-dimethylaniline (17.87 g) and tetrahydrofuran (160 ml) is added dropwise α -bromo-4-chlorophenylacetyl chloride (18.97 g) under ice cooling, and the mixture is stirred for one hour. To the reaction mixture is added ethyl acetate, and the ethyl acetate layer is washed, dried and distilled to remove the solvent. The resulting oil is dissolved in acetone (500 ml) and thereto is added potassium carbonate (40.8 g), and the mixture is refluxed for 2 hours, and acetone is distilled off. To the residue is added water, and the precipitate is separated by filtration, washed, dried and recrystallized from tetrahydrofuran to give 3-(4-chlorophenyl)-1H-naphtho[2,1-b][1,4]oxazin-2(3H)-one (13.29 g, yield 72.8 %).
M.p. 230.5 - 232°C

Example 33

1-Amino-2-naphthol and bromoacetyl chloride are reacted in the same manner as described in Example 32 to give 1H-naphtho[2,1-b][1,4]oxazin-2(3H)-one.
M.p. 219 - 220.5°C (recrystallized from tetrahydrofuran)

Example 34

To a solution of 3-(4-chlorophenyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one (38.45 g) and sodium borohydride (22.32 g) in tetrahydrofuran (1.0 liter) is added dropwise with stirring boron trifluoride etherate complex (100 ml) at room temperature, and the mixture is refluxed for 2 hours. After cooling, to the mixture are added methanol (200 ml), 10 % hydrochloric acid (300 ml) and conc. hydrochloric acid (150 ml) in this order and the mixture is further refluxed for 4 hours. To the reaction mixture is added ice water and the mixture is made alkaline with potassium carbonate and extracted with ethyl acetate. The ethyl acetate layer is washed, dried and distilled to remove the solvent. The residue is recrystallized from tetrahydrofuran-n-hexane to give 3-(4-chlorophenyl)-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (32.3 g, yield 88 %) as crystals.
M.p. 185 - 186.5°C.

Examples 35 to 44

The compounds obtained in Examples 25 to 33 are treated in the same manner as described in Example 34 to give the compounds as shown in Table 12.

Table 12

Ex. No.				
	X	R ⁵	R ⁶	M.p. (°C)
35	S	H	H	102 - 104°C *2
36	S	CH ₃	CH ₃	125 - 128°C *2
37	S	H		135.5 - 136.5°C *2
38	S	H		159 - 160.5°C *2
39	S	H		203 - 206°C *2
40A	S	H		174 - 176°C *2
40B	S	H		180 - 182°C *2
41	S	H		137 - 139°C *2
42	S	H		156 - 158°C *2
43	O	H		168 - 170°C *1
44	O	H	H	hydrochloride: 211 - 214°C *3

*1) Recrystallized from tetrahydrofuran-hexane

*2) Recrystallized from ethyl acetate-n-hexane

*3) Recrystallized from ethanol

[Note]: The compound of Example 44 is disclosed in Journal
of the Chemical Society Vol. 121, page 647.

Example 45

(1) To a suspension of 3-(4-chlorophenyl)-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (14.09 g) and triethylamine (13.7 g) in methylene chloride (300 ml) is added dropwise chloroacetyl chloride (10.2 g) under ice cooling. After the mixture is stirred at room temperature for one hour, the reaction mixture is washed, dried and distilled off to remove the solvent. The residue is crystallized from isopropyl ether to give 1-chloroacetyl-3-(4-chlorophenyl)-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (15.45 g, yield 88 %).

M.p. 172 - 174°C.







(2) To a suspension of the compound obtained above (15.45 g) and sodium iodide (13.6 g) in tetrahydrofuran (100 ml) is added diethylamine (80 ml). After the mixture is stirred at room temperature for 2 hours, the solvent and diethylamine are distilled off, and to the residue are added ethyl acetate and aqueous sodium hydrogen carbonate solution. The ethyl acetate layer is washed, dried, and concentrated to give 3-(4-chlorophenyl)-1-(diethylamino)acetyl-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (17.0 g) as an oil. The product is dissolved in ethanol and thereto is added one equivalent of fumaric acid. The resulting precipitate is recrystallized from 1 % aqueous acetone to give 3-(4-chlorophenyl)-1-(diethylamino)acetyl-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine fumarate (17.45 g, yield 81 %).

M.p. 164.5 - 166°C.

Examples 46 to 54




(1) The compounds obtained in Examples 35 to 44 are reacted with chloroacetyl chloride in the same manner as described in Example 45-(1) to give the compounds as shown in Table 13.

Table 13

Ex. No.				
	X	R ⁵	R ⁶	Physical properties, etc.
46(1)	S	CH ₃	CH ₃	caramel: Mass (m/z): 305 (M ⁺) IR $\nu_{\text{max}}^{\text{Neat}}$ (cm ⁻¹): 1675
47(1)	S	H		m.p. 156 - 157.5°C *2
48(1)	S	H		m.p. 139 - 141°C *3
49(1)	S	H		m.p. 178 - 180°C *4
50(1)	S	H		m.p. 125 - 127°C *4
51(1)	S	H		m.p. 143 - 145°C *4

- to be continued -

Table 13 (Continue)

Ex. No.				
	X	R ⁵	R ⁶	Physical properties, etc.
52(1)	S	H		m.p. 123 - 125°C *4
53(1)	O	H		m.p. 132 - 134°C *3
54(1)	O	H	H	oil: Mass (m/z): 261 (M ⁺), IR $\nu_{\text{max}}^{\text{Neat}}$ (cm ⁻¹): 1675








*2) Recrystallized from ethyl acetate-n-hexane

*3) Recrystallized from ethanol

*4) Recrystallized from isopropyl ether




(2) The products obtained in the above (1) are reacted with the corresponding amine compounds in the same manner as described in Example 45-(2) to give the compounds as shown in Tables 14 and 15.

Table 14

Ex. No.			
	R ⁵	R ⁶	Physical properties, etc.
46(2)	CH ₃	CH ₃	powder: Mass (m/z): 342 (M ⁺) IR $\nu_{\text{max}}^{\text{Nujol}}$ (cm ⁻¹): 1720, 1675
47(2)	H		m.p. 167 - 171.5°C (dec.) *5
48(2)	H		powder: Mass (m/z): 424 (M ⁺) IR $\nu_{\text{max}}^{\text{Nujol}}$ (cm ⁻¹): 1720, 1680
49(2)	H		m.p. 182 - 184°C (dec.) *5
50(2)	H		m.p. 145 - 148°C *5
51(2)	H		powder: Mass (m/z): 458 (M ⁺) IR $\nu_{\text{max}}^{\text{Nujol}}$ (cm ⁻¹): 1720, 1680
52(2)	H		powder: Mass (m/z): 458 (M ⁺) IR $\nu_{\text{max}}^{\text{Nujol}}$ (cm ⁻¹): 1720, 1680

*5) Recrystallized from ethanol-diethyl ether

Table 15
















Ex. No.				
	R ⁵	R ⁶		Physical properties, etc.
53(2)	H		N(C ₂ H ₅) ₂	oxalate: m.p. 168 - 170°C (dec.) *5
54(2)	H	H	N(CH ₃) ₂	hydrochloride: m.p. 213 - 215°C (dec.) *5

*5) Recrystallized from ethanol-diethyl ether

Examples 55 to 65

The products obtained in Examples 34, 35, 40A, 40B, 41 to 43 are reacted with the corresponding amine compounds in the same manner as described in Example 45 to give the compounds as shown in Table 16.

Table 16

Ex. No.				
	X	R ⁵		Physical properties, etc.
55	S		N(CH ₃) ₂	m.p. 217 - 219°C (dec.) *6
56	S			m.p. 209 - 211°C (dec.) *7
57	S			m.p. 234 - 236°C (dec.) *7
58	S			m.p. 239 - 240°C (dec.) *7
59	S		NHCH ₃	m.p. 238.5-240.5°C (dec.) *7
60	S	H	N(CH ₃) ₂	m.p. 215 - 216°C (dec.) *6
61	S		N(CH ₃) ₂	m.p. 143 - 146°C *5
62	S		N(CH ₃) ₂	m.p. 215 - 217°C *5
63	S		N(CH ₃) ₂	m.p. 193 - 195°C (dec.) *5
64	S		N(CH ₃) ₂	m.p. 151 - 153°C *5
65	O		N(CH ₃) ₂	m.p. 226 - 228°C (dec.) *7

*6) Recrystallized from methanol-diethyl ether

*7) Recrystallized from methanol

Example 66

To a mixture of 3-(4-chlorophenyl)-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (0.62 g), N,N-dimethylaniline (2 ml) and methylene chloride (15 ml) is added in portions dimethylaminoacetyl chloride hydrochloride (1.26 g) under ice cooling. After the mixture is stirred at room temperature for 2 hours, to the reaction mixture is added aqueous sodium hydrogen carbonate solution, and the mixture is extracted with chloroform. The chloroform layer is washed, dried and distilled to remove the solvent. The residue is purified by silica gel column chromatography (CHCl_3 : methanol = 30 : 1) to give 3-(4-chlorophenyl)-1-(dimethylamino)acetyl-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (0.36 g, 45 %) as caramel.

The compound obtained above is dissolved in ether and thereto is added one equivalent of oxalic acid. The resulting precipitate is separated by filtration and is recrystallized from methanol-diethyl ether to give 3-(4-chlorophenyl)-1-(dimethylamino)acetyl-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine oxalate.

M.p. 216 - 218°C. (dec.)

Example 67

(1) To a mixture of 3-(4-chlorophenyl)-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (1.50 g), sodium hydrogen carbonate (1.0 g), methylene chloride (30 ml) and water (15 ml) is added dropwise with stirring a solution of acryloyl chloride (0.90 g) in methylene chloride (10 ml) under ice cooling. The mixture is stirred at room temperature for 3 hours. The organic layer is separated, washed, dried and distilled to remove the solvent. The residue is chromatographed on silica gel (toluene : acetone = 50 : 1) to give 3-(4-chlorophenyl)-1-propenoyl-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (1.37 g, 78 %) as powder.

Mass (m/z): 365 (M^+)

IR $\nu_{\text{max}}^{\text{Nujol}}$ (cm^{-1}): 1660, 1620

(2) To a suspension of the compound obtained above (1.33 g) in tetrahydrofuran (10 ml) is added dropwise a 17 % solution of dimethylamine in methanol (15 ml). After the mixture is stirred at room temperature for one hour, the solvent is distilled off to give 3-(4-chlorophenyl)-1-[3-(dimethylamino)propionyl]-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (1.39 g) as caramel.



The compound obtained above is dissolved in ether, and thereto is added one equivalent of oxalic acid. The resulting precipitate is separated by filtration and recrystallized from methanol to give 3-(4-chlorophenyl)-1-[3-(dimethylamino)propionyl]-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine oxalate.

M.p. 217 - 219°C. (dec.)

Examples 69 to 70

The corresponding starting materials are treated in the same manner as described in Example 24 to give the compounds as shown in Table 17.

Table 17

Ex. No.			
	R ⁵	R ⁶	M.p.
69	CH ₃	H	179.5 - 181°C *1
70		H	215.5 - 217.5°C *1

*1) Recrystallized from tetrahydrofuran-n-hexane

*8) Recrystallized from tetrahydrofuran-diisopropyl ether

Example 71

(1) A mixture of 1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one (5.17 g), 4-chlorobenzaldehyde (5.62 g), sodium methoxide (1.73 g) and dimethylformamide (80 ml) is refluxed for 4.5 hours. After cooling, the reaction mixture is poured into water and the resulting precipitate is separated by filtration, washed and dried and then is recrystallized from tetrahydrofuran-n-hexane to give 3-(4-chlorobenzylidene)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one (4.28 g). M.p. 277 - 279°C.

(2) A mixture of the compound obtained above (4.0 g), 10 % palladium on charcoal (2.0 g), tetrahydrofuran (200 ml) and ethanol (40 ml) is stirred under hydrogen gas under atmospheric pressure for 3 hours. After the reaction is completed, 10 % palladium-carbon is removed by filtration, and the solvent is distilled off. The residue is recrystallized from ethyl acetate-n-hexane to give 3-(4-chlorobenzyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one (3.20 g). M.p. 185 - 186°C.

Example 72

To a mixture of 1-amino-2-naphthol (16.9 g), N,N-dimethylaniline (19.3 g) and tetrahydrofuran (200 ml) is added dropwise chloroacetyl chloride under ice cooling, and the mixture is stirred at the same temperature for one hour. To the reaction mixture is added ethyl acetate, and the ethyl acetate layer is washed, dried and distilled to remove the solvent. The resulting oil is dissolved in acetone (500 ml) and thereto is added potassium carbonate (75 g), and the mixture is refluxed for 2 hours, and acetone is distilled off. To the residue is added water, and the precipitate is separated by filtration, washed, dried and recrystallized from tetrahydrofuran to give 1H-naphtho[2,1-b][1,4]oxazin-2(3H)-one (13.1 g). M.p. 219 - 220.5°C

Example 73

(1) To a solution of 3-(4-chlorophenyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one (10.0 g) and 96 % sodium hydroxide (1.96 g) in dimethylsulfoxide (150 ml) is added 1-bromo-3-chloropropan (6.78 g) under ice cooling, and the mixture is stirred at room temperature overnight. The reaction mixture is poured into water, and the mixture is extracted with

ethyl acetate. The ethyl acetate layer is washed and distilled to remove the solvent. The residue is purified by silica gel column chromatography (eluent; n-hexane : ethyl acetate = 5 : 1) and further is recrystallized from methanol to give 3-(4-chlorophenyl)-1-(3-chloropropyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one (8.04 g). M.p. 110 - 112.5°C.





(2) A mixture of the compound obtained above (1.0 g), diethylamine (3.72 g), sodium iodide (1.5 g), potassium carbonate (1.8 g) and acetone (50 ml) is refluxed overnight. The reaction mixture is distilled to remove the solvent, and to the residue is added water, and the mixture is extracted with ethyl acetate. The extract is distilled to remove the solvent. The residue is purified by silica gel column chromatography (eluent; chloroform : methanol = 20 : 1) to give 3-(4-chlorophenyl)-1-[3-(diethylamino)propyl]-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one as oil.

To a solution of the compound obtained above in ether is added one equivalent of oxalic acid, and the resulting precipitate is separated by filtration and recrystallized from ethanol-diethyl ether to give 3-(4-chlorophenyl)-1-[3-(diethylamino)propyl]-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one oxalate (0.75 g). M.p. 190.5 - 192.5°C. (dec.)

Examples 74 to 75

(1) The compound obtained in Example 24 is treated in the same manner as described in Example 73 to give the compounds as shown in Table 18.

Table 18

Ex. No.		
		M.p. etc.
74		hydrochloride: 224.5 - 227°C *5
75		oxalate: 184.5 - 187.5°C (dec.) *3

*3) Recrystallized from ethanol

*5) Recrystallized from ethanol-diethyl ether

Example 76

A mixture of 3-(3-trifluoromethylphenyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one (18.0 g), potassium carbonate (24.2 g), 3-(dimethylamino)propyl chloride hydrochloride (9.5 g), acetone (400 ml) and water (4 ml) is refluxed for 48 hours. The insoluble materials are filtered off and acetone is distilled off, and to the residue are added ethanol (200 ml) and 10 % hydrochloric acid (100 ml), and the mixture is refluxed for one hour. After ethanol is distilled off and the insoluble materials are filtered off, the resulting mixture is made alkaline with sodium hydrogen carbonate and extracted with ethyl acetate. The extract is distilled to remove the solvent to give 1-[3-(dimethylamino)propyl]-3-(3-trifluoromethylphenyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one as oil.









Mass (m/z): 444 (M⁺)

To a solution of the compound obtained above in ether is added one equivalent of oxalic acid, and the resulting precipitate is separated by filtration and recrystallized from ethanol-diethyl ether to give 1-[3-(dimethylamino)propyl]-3-(3-trifluoromethylphenyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one oxalate (16.23 g).
M.p. 130 - 133°C.

Examples 77 to 87

The compounds obtained in Examples 24, 25B, 26, 28-29, 69-72 are treated in the same manner as described in Example 76 to give the compounds as shown in Tables 19 to 21.

Table 19

Ex. No.				
	R ⁵	R ⁶	A	M.p.
77	CH ₃	H	-(CH ₂) ₃ -	oxalate: 163-165°C *5
78	CH ₃	CH ₃	-(CH ₂) ₃ -	oxalate: 169-170°C *5
79		H	-(CH ₂) ₃ -	oxalate: 93°C (dec.) *9
80		H	-(CH ₂) ₂ -	oxalate: 220-221.5°C (dec.) *7
81		H	-(CH ₂) ₃ -	oxalate: 235-236.5°C (dec.) *6
82		H	-(CH ₂) ₃ -	oxalate: 190-192.5°C (dec.) *3
83		H	-(CH ₂) ₂ -	hydrochloride: 208.5-211.5°C *9
84		H	-(CH ₂) ₃ -	hydrochloride: 183-185.5°C *5
85		H	-(CH ₂) ₃ -	hydrochloride: 219-222°C *5

*3) Recrystallized from ethanol



*5) Recrystallized from ethanol-diethyl ether

*5) Recrystallized from methanol-diethyl ether

*7) Recrystallized from methanol


*9) Recrystallized from ethyl acetate

Table 20

Ex. No.	 • oxalate			
	R ⁵	A	-N ^{R⁷} _{R⁸}	M.p.
86	-CH ₂ -  -Cl	-(CH ₂) ₃ -	-N ^{CH₃} _{CH₃}	174-176°C (dec.) *3

*3) Recrystallized from ethanol

Table 21

Ex. No.	 • HCl	
	R ⁵	M.p.
87	H	136.5-139.5°C *5

*5) Recrystallized from ethanol-diethyl ether

Example 88

To a mixture of 3-(4-chlorophenyl)-1-[3-(methylamino)propyl]-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one (1.79 g), potassium carbonate (2.18 g) and acetone (50 ml) is added allyl bromide (0.65 g) under ice cooling, and the mixture is stirred at room temperature overnight. The insoluble materials are filtered off and acetone is distilled off, and the oily residue is purified by silica gel column chromatography (eluent, chloroform : methanol = 20 : 1) to give 1-[3-(N-allyl-N-methylamino)propyl]-3-(4-chlorophenyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one as oil.

To a solution of the compound obtained above in ether is added one equivalent of oxalic acid, and the resulting precipitate is separated by filtration and recrystallized from ethanol-diethyl ether to give 1-[3-(N-allyl-N-methylamino)propyl]-3-(4-chlorophenyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one oxalate (1.52 g).
M.p. 172.5 - 175.5°C. (dec.)

Example 89

The compound obtained in Example 74 is treated in the same manner as described in Example 88 to give 3-(4-chlorophenyl)-1-[3-[N-methyl-N-(2-propynyl)amino]propyl]-1H-naphtho-[2,1-b][1,4]thiazin-2(3H)-one.

Oxalate: m.p. 166 - 169°C (dec., recrystallized from ethanol-diethyl ether).

Example 90

(1) To a solution of (±)-2-(4-chlorophenyl)-3,4-dihydro-2H-1,4-benzothiazine (10.01 g, 0.038 mole) in pyridine (150 ml) is added (S)-N-(2-naphthalenesulfonyl)propyl chloride (18.57 g, 0.057 mole), and the mixture is stirred at room temperature for 4 hours. To the reaction mixture is added ethyl acetate, and the mixture is washed with 5 % hydrochloric acid, water, aqueous sodium hydrogen carbonate solution, water and saline in this order, and the ethyl acetate layer is separated, dried over sodium sulfate and distilled to remove the solvent. The resulting caramel is subjected to silica gel column chromatography (hexane : ethyl acetate = 5 : 1 - 3 : 1). From the fraction eluted first there is obtained (R)-2-(4-chlorophenyl)-4-[(S)-N-(2-naphthalenesulfonyl)propyl]-3,4-dihydro-2H-1,4-benzothiazine (10.75 g, 51 %) as crystals. M.p. 147 - 151°C.

Besides, from the fraction eluted subsequently there is obtained (S)-2-(4-chlorophenyl)-4-[(S)-N-(2-naphthalenesulfonyl)propyl]-3,4-dihydro-2H-1,4-benzothiazine (7.58 g, 36 %) as crystals. M.p. 171 - 174.5°C.

(2) (R)-2-(4-Chlorophenyl)-4-[(S)-N-(2-naphthalenesulfonyl)propyl]-3,4-dihydro-2H-1,4-benzothiazine (9.40 g, 0.017 mole) is suspended in ethanol-water (10 : 1, 188 ml), and thereto is added 86 % potassium hydroxide (11.2 g, 0.172 mole), and the mixture is refluxed for 30 minutes. The reaction mixture is poured into ice water and the mixture is extracted with ethyl acetate. The ethyl acetate layer is washed with water and saline, dried over sodium sulfate and distilled to remove the solvent. The residue is purified by silica gel column chromatography (CHCl₃) and thereafter recrystallized from ethyl acetate-hexane twice to give (R)(+)-2-(4-chlorophenyl)-3,4-dihydro-2H-1,4-benzothiazine (2.61 g, 58 %).

M.p. 151 - 153°C.

$[\alpha]_D^{20} +38.0^\circ$ (c = 1.0, CHCl₃).

In the same manner as described above, (S)-2-(4-chlorophenyl)-4-[(S)-N-(2-naphthalenesulfonyl)propyl]-3,4-dihydro-2H-1,4-benzothiazine (7.26 g, 0.0132 mole) is treated to give (S)-(-)-2-(4-chlorophenyl)-3,4-dihydro-2H-1,4-benzothiazine (2.45 g, 71 %). M.p. 151 - 152.5°C.

$[\alpha]_D^{20} -38.4^\circ$ (c = 1.0, CHCl₃).

(3) To a suspension of (R)-(+)-2-(4-chlorophenyl)-3,4-dihydro-2H-1,4-benzothiazine (1.30 g, 0.005 mole) and triethylamine (1.66 ml, 0.012 mole) in dichloromethane (16 ml) is added dropwise a solution of chloroacetyl chloride (0.79 ml, 0.01 mole) in dichloromethane (4 ml) under ice cooling, and the mixture is stirred at room temperature for 45 minutes. After the solvent is distilled off, to the residue are added ethyl acetate and water, and the ethyl acetate layer is washed with aqueous sodium hydrogen carbonate solution, water and saline, dried over sodium sulfate and distilled to remove the solvent to give (R)-4-chloroacetyl-2-(4-chlorophenyl)-3,4-dihydro-2H-1,4-benzothiazine (1.84 g) as caramel.

A mixture of the above-obtained compound, diethylamine (8 ml), sodium iodide (1.49 g, 0.01 mole) and tetrahydrofuran (24 ml) is stirred at room temperature for 30 minutes, and the volatiles are distilled off. To the residue are added ethyl acetate and aqueous sodium hydrogen carbonate solution, and the ethyl acetate layer is washed with water and saline, dried over sodium sulfate and distilled to remove the solvent. The residue is purified by silica gel column chromatography (CHCl₃ : methanol = 50 : 1) to give (R)-(+)-2-(4-chlorophenyl)-4-diethylaminoacetyl-3,4-dihydro-2H-1,4-benzothiazine (1.74 g, 94 %) as caramel. Mass (m/z): 376, 374 (M⁺)

Oxalate (recrystallized from ethanol):

M.p. 133 - 135°C (decomp.)

$[\alpha]_D^{20} +111.9^\circ$ (c = 1.0, H₂O).

In the same manner as described above, (S)-(-)-2-(4-chlorophenyl)-3,4-dihydro-2H-1,4-benzothiazine (1.30 g, 0.005 mole) is treated to give (S)-(-)-2-(4-chlorophenyl)-4-diethylaminoacetyl-3,4-dihydro-2H-1,4-benzothiazine (1.72 g, 92 %) as caramel. Mass (m/z): 376, 374 (M⁺)

Oxalate (recrystallized from ethanol):

M.p. 133 - 135°C (decomp.)

$[\alpha]_D^{20} -112.6^\circ$ (c = 1.0, H₂O).

Example 91

(±)-2-(4-Chlorophenyl)-4-diethylaminoacetyl-3,4-dihydro-2H-1,4-benzothiazine (68.54 g, 0.183 mole) and (2S, 3S)-3-[(5-chloro-2-nitrophenyl)thio]-2-hydroxy-3-(4-methoxyphenyl)propionic acid (70.16 g, 0.183 mole) are dissolved in

ethyl acetate (one liter), and the mixture is concentrated to about 500 ml and then allowed to stand. The resulting precipitate is separated by filtration and recrystallized from ethyl acetate twice to give a salt of (R)-isomer (30.80 g) as crystals. M.p. 153 - 154°C.

The above-obtained compound is treated with diethyl ether-aqueous sodium hydrogen carbonate solution to convert into free base. The product is treated with HCl-ethanol to convert into hydrochloride. This product is recrystallized from ethanol-diethyl ether to give (R)-(+)-2-(4-chlorophenyl)-4-diethylaminoacetyl-3,4-dihydro-2H-1,4-benzothiazine hydrochloride (12.88 g, 17 %) as crystals.

M.p. 211.5 - 212.5°C.

$[\alpha]_D^{20} +128.6^\circ$ (c = 1.0, H₂O)

In the same manner as described above except that (2R, 3R)-3-[(5-chloro-2-nitrophenyl)thio]-2-hydroxy-3-(4-methoxyphenyl)propionic acid is used as the resolving agent, there is obtained (S)-(-)-2-(4-chlorophenyl)-4-diethylaminoacetyl-3,4-dihydro-2H-1,4-benzothiazine hydrochloride.

M.p. 211 - 212.5°C

$[\alpha]_D^{20} -126.5^\circ$ (c = 1.0, H₂O)

Example 92

(1) A mixture of 3-(4-chlorophenyl)-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (25.0 g, 0.080 mole), (S)-N-(2-naphthalenesulfonyl)propyl chloride (25.96 g, 0.080 mole) and benzene (800 ml) is stirred at 60°C for 24 hours. The insoluble materials are removed by filtration, and to the filtrate is added ethyl acetate, and the mixture is washed with 5 % hydrochloric acid, water, aqueous sodium hydrogen carbonate solution, water and saline in this order, and the ethyl acetate layer is dried over sodium sulfate and distilled to remove the solvent. The residue is subjected to silica gel column chromatography (ethyl acetate : hexane = 1 : 3). From the fraction eluted first there is obtained (R)-3-(4-chlorophenyl)-1-[(S)-N-(2-naphthalenesulfonyl)propyl]-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (11.97 g, 25 %) as caramel.

Mass (m/z): 600, 598 (M⁺)

IR $\nu_{\text{max}}^{\text{neat}}$ cm⁻¹: 1680

Besides, from the fraction eluted subsequently there is obtained (S)-3-(4-chlorophenyl)-1-[(S)-N-(2-naphthalenesulfonyl)propyl]-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (12.13 g, 25.3 %) as crystals. M.p. 204 - 205°C.

(2) A mixture of (R)-3-(4-chlorophenyl)-1-[(S)-N-(2-naphthalenesulfonyl)propyl]-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (11.50 g, 0.019 mole), 86 % potassium hydroxide (15.0 g, 0.227 mole) and ethanol-water (10 : 1, 230 ml) is refluxed under argon for one hour. The reaction mixture is poured into ice water and the mixture is extracted with ethyl acetate. The ethyl acetate layer is washed with water and saline, dried over sodium sulfate and distilled to remove the solvent. The residue is purified by silica gel column chromatography (CHCl₃) and thereafter recrystallized from ethyl acetate-hexane to give (R)-(+)-3-(4-chlorophenyl)-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (3.74 g, 63 %). M.p. 205 - 206°C.

$[\alpha]_D^{20} +121.7^\circ$ (c = 1.0, CHCl₃).

In the same manner as described above, (S)-3-(4-chlorophenyl)-1-[(S)-N-(2-naphthalenesulfonyl)propyl]-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (11.50 g, 0.019 mole) is treated to give (S)-(-)-3-(4-chlorophenyl)-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (3.09 g, 52 %).

M.p. 206 - 207°C.

$[\alpha]_D^{20} -121.1^\circ$ (c = 1.0, CHCl₃).

(3) To a suspension of (R)-(+)-3-(4-chlorophenyl)-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (2.0 g, 0.0064 mole) and triethylamine (2.1 ml, 0.015 mole) in dichloromethane (30 ml) is added dropwise a solution of chloroacetyl chloride (1.0 ml, 0.0126 mole) in dichloromethane (5 ml) under ice cooling, and the mixture is stirred at room temperature for 45 minutes. After the volatiles are distilled off, to the residue are added ethyl acetate and water, and the ethyl acetate layer is washed with aqueous sodium hydrogen carbonate solution, water and saline, dried over sodium sulfate and distilled to remove the solvent. The residue is purified by silica gel column chromatography (ethyl acetate : hexane = 1 : 4) to give (R)-1-chloroacetyl-3-(4-chlorophenyl)-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (2.40 g, 96 %) as caramel.

A mixture of the above-obtained compound (1.20 g, 0.0031 mole), sodium iodide (0.93 g, 0.0062 mole) and 10 % solution of dimethylamine in tetrahydrofuran (25 ml) is stirred at room temperature for 5.5 hours, and the solvent is distilled off. To the residue are added ethyl acetate and aqueous sodium hydrogen carbonate solution, and the ethyl acetate layer is washed with water and saline, dried over sodium sulfate and distilled to remove the solvent. The residue is purified by silica gel column chromatography (CHCl₃ : methanol = 50 : 1) to give (R)-(+)-3-(4-chlorophenyl)-1-dimethylaminoacetyl-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (1.15 g, 94 %) as caramel. Mass (m/z): 398, 396 (M⁺)

Oxalate (recrystallized from methanol-diethyl ether):

M.p. 215.5 - 216.5°C. (decomp.)

$[\alpha]_D^{20} +297.0^\circ$ (c = 1.0, DMF)

In the same manner as described above, (S)-(-)-3-(4-chlorophenyl)-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (0.98 g, 0.0031 mole) is treated to give (S)-(-)-3-(4-chlorophenyl)-1-dimethylaminoacetyl-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine (1.19 g, 95.0 %) as caramel. Mass (m/z): 398, 396 (M⁺)

Oxalate (recrystallized from methanol-diethyl ether):

M.p. 215 - 216.5°C. (decomp.)

$[\alpha]_D^{20} -296.6^\circ$ (c = 1.0, DMF)

10 Example 93

The corresponding starting material is treated in the same manner as described in Example 92, there is obtained (R)-(+)-and (S)-(-)-3-(4-chlorophenyl)-1-diethylaminoacetyl-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine oxalate.

(R)-(+)-isomer (oxalate: recrystallized from acetone):

15 M.p. 137 - 140°C. $[\alpha]_D^{20} +322.7^\circ$ (c = 1.0, methanol)

(S)-(-)-isomer (oxalate: recrystallized from acetone):

M.p. 138 - 140.5°C.

$[\alpha]_D^{20} -321.7^\circ$ (c = 1.0, methanol)

20 Example 94

(±)-1-Dimethylaminopropyl-3-(3-trifluoromethylphenyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one (7.53 g, 0.0169 mole) and (2R, 3R)-3-[(5-chloro-2-nitrophenyl)thio]-2-hydroxy-3-(4-methoxyphenyl)propionic acid (6.50 g, 0.0169 mole) are dissolved in ethyl acetate, and the mixture is concentrated and thereto is added diethyl ether, and the mixture is allowed to stand overnight. The resulting precipitate is separated by filtration and recrystallized from ethyl acetate twice to give a salt of (+)-isomer (3.04 g, 22 %) as crystals. M.p. 147 - 148°C.

The above-obtained compound (2.80 g) is stirred in diethyl ether-aqueous sodium hydrogen carbonate solution. The diethyl ether layer is washed with water, dried and distilled to remove the solvent to give (+)-1-dimethylaminopropyl-3-(3-trifluoromethylphenyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one (1.42 g, 94 %) as oil.

30 Mass (m/z): 444 (M⁺)

IR ν_{\max}^{neat} cm⁻¹: 1670

$[\alpha]_D^{20} +80.1^\circ$ (c = 1.0, CHCl₃).

Oxalate:

M.p. 101 - 104°C.

35 $[\alpha]_D^{20} +115.9^\circ$ (c = 1.0, methanol)

In the same manner as described above except that (2S, 3S)-3-[(5-chloro-2-nitrophenyl)thio]-2-hydroxy-3-(4-methoxyphenyl)propionic acid is used as the resolving agent, there is obtained (-)-1-dimethylaminopropyl-3-(3-trifluoromethylphenyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one as oil.

Mass (m/z): 444 (M⁺)

40 IR ν_{\max}^{neat} cm⁻¹: 1670

$[\alpha]_D^{20} -80.5^\circ$ (c = 1.0, CHCl₃).

Oxalate:

M.p. 102 - 106°C.

$[\alpha]_D^{20} -118.6^\circ$ (c = 1.0, methanol)

45

[Preparation of starting materials]

Reference Example 1

50 To a suspension of 2-aminothiophenol (12.6 g) and sodium acetate (23.6 g) in ethanol (150 ml) is added methyl α-bromo-4-fluorophenylacetate (23.6 g), and the mixture is stirred at room temperature overnight. After the solvent is distilled off, water is added to the residue. The resulting precipitate is separated by filtration, washed, dried, and then recrystallized from tetrahydrofuran-n-hexane to give 2-(4-fluorophenyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine (21.7 g) as crystals. M.p. 216 - 219°C.

55

Reference Examples 2 to 4

The corresponding starting materials are treated in the same manner as described in Reference Example 1 to give the compounds as shown in Table 22.

Table 22

Ref. Ex. No.		
	R ⁵	M.p. (solvent for recrystal.)
2		159 - 161.5°C (tetrahydrofuran-n-hexane)
3		227 - 229°C (tetrahydrofuran-n-hexane)
4		199 - 201°C (tetrahydrofuran-n-hexane)

Reference Example 5

To a solution of 2-amino-5-chlorothiophenol (4.49 g) in ethanol (30 ml) is added 96 % potassium hydroxide (1.63 g), and the mixture is distilled to remove ethanol. The resulting solid material is suspended in toluene (70 ml) and thereto is added methyl α -bromo-4-chlorophenylacetate (7.38 g), and the mixture is refluxed overnight. The reaction mixture is concentrated, and the resulting precipitate is separated by filtration, washed, dried, and then recrystallized from tetrahydrofuran-n-hexane to give 7-chloro-2-(4-chlorophenyl)-3-oxo-3,4-dihydro-2H-1,4-benzothiazine (6.58 g) as crystals. M.p. 230 - 233.5°C.



Reference Example 6

To a solution of 2-chloro-3-oxo-3,4-dihydro-2H-1,4-benzothiazine (9.38 g) and thiophene (7.91 g) in methylene chloride (250 ml) is added in portions stannic chloride (12.2 g) at 0 to 5°C. After stirring at the same temperature for 45 minutes, the mixture is poured into ice water, and the organic layer is separated. The aqueous layer is extracted with ethyl acetate, and the ethyl acetate layer is combined with the above organic layer and distilled to remove the solvent. The resulting solid material is recrystallized from ethanol to give 3-oxo-2-(2-thienyl)-3,4-dihydro-2H-1,4-benzothiazine (8.17 g) as crystals. M.p. 174 - 177°C.

Reference Example 7

The corresponding starting materials are treated in the same manner as described in Reference Example 6 to give the compound as shown in Table 23.

Table 23

Ref. Ex. No.		
	R ⁵	M.p. (solvent for recrystal.)
7		246.5 - 247.5°C (tetrahydrofuran-ethanol)


Reference Example 8

To a solution of 2-aminophenol (13.5 g) in ethyl acetate (150 ml) is added a solution of sodium hydrogen carbonate (15 g) in water (300 ml), and to the mixture is added dropwise a solution of α -bromo-4-chlorophenylacetyl chloride (32.2 g) in toluene with vigorous stirring under ice cooling. After the mixture is stirred at room temperature for one hour, the solvent in the organic layer is distilled off and the residue is dissolved in acetone. To the solution is added potassium carbonate (20 g), and the mixture is stirred at room temperature overnight. The solvent is distilled off and to the residue is added water. The mixture is extracted with ethyl acetate. The ethyl acetate layer is washed, dried and distilled to remove the solvent, and the residue is recrystallized from ethyl acetate-n-hexane to give 2-(4-chlorophenyl)-3-oxo-3,4-dihydro-2H-1,4-benzoxazine (24.0 g) as crystals. M.p. 180.5 - 181.5°C.

Claims

Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE


- 1. A thiazine or oxazine derivative of the following formula [I]:**



wherein R¹ and R² are both hydrogen atom or form a naphthalene ring together with the benzene ring; R³ and R⁴ are both hydrogen atom, or one of them is a halogen atom and another is hydrogen atom; X is sulfur atom or oxygen atom; R⁵ and R⁶ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₃₋₈ cycloalkyl, iv) a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, v) naphthyl, vi) a C₁₋₆ alkyl which is substituted by a phenyl or a phenyl having one or two substituents


- selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or vii) a sulfur-containing monoheterocyclic group; one of Z¹ and Z² is oxygen atom and another is two hydrogen atoms; A is a C₁₋₆ alkylene; R⁷ and R⁸ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₂₋₆ alkenyl, iv) a C₂₋₆ alkynyl, or v) a C₁₋₆ alkyl which is substituted by a phenyl or a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or both form together with the adjacent nitrogen atom a nitrogen-containing monoheterocyclic group; provided that when both of R¹ and R² are hydrogen atom, Z² is oxygen atom and either one of R⁵ and R⁶ is a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, naphthyl or a sulfur-containing monoheterocyclic group, or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, wherein R³ and R⁴ are both hydrogen atom; R⁵ and R⁶ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₃₋₈ cycloalkyl, iv) a phenyl having 1 or 2 substituents selected from a halogen atom, a trihalogeno (C₁₋₆) alkyl and a C₁₋₆ alkyl, v) naphthyl, or vi) thienyl; and R⁷ and R⁸ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₂₋₆ alkenyl, or iv) a C₂₋₆ alkynyl, or both form together with the adjacent nitrogen atom a nitrogen-containing monoheterocyclic group selected from morpholinyl, pyrrolidinyl and piperidyl; provided that when both of R¹ and R² are hydrogen atom, Z² is oxygen atom and either one of R⁵ and R⁶ is i) a phenyl having 1 or 2 substituents selected from a halogen atom, a trihalogeno (C₁₋₆) alkyl and a C₁₋₆ alkyl, ii) naphthyl or iii) thienyl.
3. A compound according to claim 1, wherein one of R⁵ and R⁶ is hydrogen atom and another is i) a C₃₋₈ cycloalkyl, ii) a phenyl having 1 or 2 substituents selected from a halogen atom, a trihalogeno (C₁₋₆) alkyl and a C₁₋₆ alkyl, iii) naphthyl, or iv) a halogenophenyl-substituted C₁₋₆ alkyl; and R⁷ and R⁸ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₂₋₆ alkenyl, iv) a C₂₋₆ alkynyl, or v) a C₁₋₆ alkyl substituted by a di(C₁₋₆)alkoxyphenyl, or both form together with the adjacent nitrogen atom a nitrogen-containing monoheterocyclic group selected from morpholinyl, pyrrolidinyl, piperidinyl and imidazolyl; provided that when both of R¹ and R² are hydrogen atom, Z² is oxygen atom and either one of R⁵ and R⁶ is i) a phenyl having 1 or 2 substituents selected from a halogen atom, a trihalogeno(C₁₋₆)alkyl and a C₁₋₆ alkyl, or ii) naphthyl.
4. A compound according to claim 1, wherein R³ and R⁴ are both hydrogen atom; one of R⁵ and R⁶ is hydrogen atom and another is i) a C₃₋₈ cycloalkyl, ii) a phenyl having 1 or 2 substituents selected from a halogen atom, a trihalogeno (C₁₋₆) alkyl and a C₁₋₆ alkyl, or iii) naphthyl; and R⁷ and R⁸ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₂₋₆ alkenyl, or iv) a C₂₋₆ alkynyl, or both form together with the adjacent nitrogen atom piperidyl; provided that when both of R¹ and R² are hydrogen atom, Z² is oxygen atom and either one of R⁵ and R⁶ is i) a phenyl having 1 or 2 substituents selected from a halogen atom, a trihalogeno (C₁₋₆) alkyl and a C₁₋₆ alkyl, or ii) naphthyl.
5. A compound according to claim 4, wherein X is a sulfur atom.
6. The compound according to claim 5, wherein one of R⁵ and R⁶ is hydrogen atom and another is halogenophenyl or a trihalogeno(C₁₋₆)alkylphenyl, and R⁷ and R⁸ are the same or different and are each a C₁₋₆ alkyl.
7. A compound according to claim 5, wherein one of R⁵ and R⁶ is hydrogen atom and another is chlorophenyl or trifluoromethylphenyl, and R⁷ and R⁸ are both methyl or ethyl.
8. 2-(4-Chlorophenyl)-4-(diethylamino)acetyl-3,4-dihydro-2H-1,4-benzothiazine or a pharmaceutically acceptable salt thereof.
9. 3-(4-Chlorophenyl)-1-(diethylamino) acetyl-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine or a pharmaceutically acceptable salt thereof.
10. 1-[3-(dimethylamino)propyl]-3-(3-trifluoromethylphenyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition which comprises an amount of a thiazine or oxazine as claimed in any one of the preceding claims in admixture with a pharmaceutically acceptable carrier or diluent.

12. A process for preparing a thiazine or oxazine derivative of the following formula [I]:



15 wherein R¹ and R² are both hydrogen atom or form a naphthalene ring together with the benzene ring; R³ and R⁴ are both hydrogen atom, or one of them is a halogen atom and another is hydrogen atom; X is sulfur atom or oxygen atom; R⁵ and R⁶ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₃₋₈ cycloalkyl, iv) a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, v) naphthyl, vi) a C₁₋₆ alkyl which is substituted by a phenyl or a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or vii) a sulfur containing monoheterocyclic group; one of Z¹ and Z² is oxygen atom and another is two hydrogen atoms; A is a C₁₋₆ alkylene; R⁷ and R⁸ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₂₋₆ alkenyl, iv) a C₂₋₆ alkynyl, or v) a C₁₋₆ alkyl which is substituted by a phenyl or a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or both form together with the adjacent nitrogen atom a nitrogen-containing monoheterocyclic group; provided that when both of R¹ and R² are hydrogen atom, Z² is oxygen atom and either one of R⁵ and R⁶ is a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, naphthyl or a sulfur-containing monoheterocyclic group, or a pharmaceutically acceptable salt thereof, which comprises the steps of


30 (a) reacting a compound of the formula:



45 wherein R¹, R², R³, R⁴, R⁵, R⁶, X and Z¹ are as defined above or a salt thereof with a compound of the formula:



wherein Y^1 and Y^2 are the same or different and are each a reactive residue, and A and Z^2 are as defined above, to give a compound of the formula:




15 wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , X, A, Z^1 , Z^2 and Y^1 are as defined above, and then reacting the above compound [IV] with an amine compound of the formula:



25 wherein R^7 and R^8 are as defined above, or a salt thereof, or

(b) reacting the compound of the formula [II] or a salt thereof with a compound of the formula:




35 wherein Y^3 is a reactive residue, and Z^2 , A, R^7 and R^8 are as defined above, or

(c) in case of the compound [I] wherein A is ethylene, Z^1 is two hydrogen atom, and Z^2 is oxygen atom, reacting the compound of the formula [II] or a salt thereof with an acrylic acid compound of the formula:




wherein Y^2 is as defined above, to give a compound of the formula:



55 wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , and X are as defined above, and then reacting the above compound [VIII] with an amine compound [V], or a salt thereof, or

(d) in case of the compounds [I] wherein at least one of R^7 and R^8 is a C_{1-6} alkyl, a C_{2-6} alkenyl, a C_{2-6} alkynyl, or a C_{1-6} alkyl which is substituted by a phenyl or a phenyl having one or two substituents selected from a

halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, reacting a compound of the formula:



15


wherein R¹, R², R³, R⁴, R⁵, R⁶, X, A, Z¹, and Z² are as defined above, and R⁷¹ is hydrogen atom, a C₁₋₆ alkyl, a C₂₋₆ alkenyl, a C₂₋₆ alkynyl, or a C₁₋₆ alkyl which is substituted by a phenyl or a phenyl having one or two substituents selected from a halogen atom, a trihalogen C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or a salt thereof with a compound of the formula:



25

wherein R⁸¹ is a C₁₋₆ alkyl, a C₂₋₆ alkenyl, a C₂₋₆ alkynyl, or a C₁₋₆ alkyl which is substituted by a phenyl or a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, and Y⁴ is a reactive residue, optionally followed by converting the compound [I] in the free form into a pharmaceutically acceptable salt thereof.

13. A compound of the formula:



40


45

wherein X' is sulfur atom or oxygen atom; R⁵¹ and R⁶¹ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₃₋₈ cycloalkyl, iv) a phenyl having one or two substituents selected from a halogen atom, a trihalogen C₁₋₆ alkyl, C₁₋₆ alkyl and a C₁₋₆ alkoxy, v) naphthyl, vi) a C₁₋₆ alkyl which is substituted by a phenyl or a phenyl having one or two substituents selected from a halogen atom, a trihalogen C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or vii) a sulfur-containing monoheterocyclic group; Z¹¹ is oxygen atom or is two hydrogen atoms; provided that when Z¹¹ is two hydrogen atoms and R⁵¹ and R⁶¹ are both hydrogen atom, X' is sulfur atom, or a salt thereof.

14. The use of a compound as claimed in any one of claims 1 to 12 in the preparation of a medicament for the prophylaxis and treatment of ischemicencephalopathia and/or cerebral neurocyte dyscrasia.


Claims for the following Contracting States : ES, GR

1. A process for preparing a pharmaceutical composition which comprises admixing a thiazine or oxazine derivative of the following formula [I]:




- wherein R¹ and R² are both hydrogen atom or form a naphthalene ring together with the benzene ring; R³ and R⁴ are both hydrogen atom, or one of them is a halogen atom and another is hydrogen atom; X is sulfur atom or oxygen atom; R⁵ and R⁶ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₃₋₈ cycloalkyl, iv) a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, v) naphthyl, vi) a C₁₋₆ alkyl which is substituted by a phenyl or a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or vii) a sulfur-containing monoheterocyclic group; one of Z¹ and Z² is oxygen atom and another is two hydrogen atoms; A is a C₁₋₆ alkylene; R⁷ and R⁸ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₂₋₆ alkenyl, iv) a C₂₋₆ alkynyl, or v) a C₁₋₆ alkyl which is substituted by a phenyl or a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or both form together with the adjacent nitrogen atom a nitrogen-containing monoheterocyclic group; provided that when both of R¹ and R² are hydrogen atom, Z² is oxygen atom and either one of R⁵ and R⁶ is a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, naphthyl or a sulfur-containing monoheterocyclic group, or a pharmaceutically acceptable salt thereof with a pharmaceutically acceptable carrier or diluent.
2. A process according to claim 1, wherein R³ and R⁴ are both hydrogen atom; R⁵ and R⁶ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₃₋₈ cycloalkyl, iv) a phenyl having 1 or 2 substituents selected from a halogen atom, a trihalogeno (C₁₋₆) alkyl and a C₁₋₆ alkyl, v) naphthyl, or vi) thienyl; and R⁷ and R⁸ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₂₋₆ alkenyl, or iv) a C₂₋₆ alkynyl, or both form together with the adjacent nitrogen atom a nitrogen-containing monoheterocyclic group selected from morpholinyl, pyrrolidinyl and piperidyl; provided that when both of R¹ and R² are hydrogen atom, Z² is oxygen atom and either one of R⁵ and R⁶ is i) a phenyl having 1 or 2 substituents selected from a halogen atom, a trihalogeno (C₁₋₆) alkyl and a C₁₋₆ alkyl, ii) naphthyl or iii) thienyl.
3. A process according to claim 1, wherein one of R⁵ and R⁶ is hydrogen atom and another is i) a C₃₋₈ cycloalkyl, ii) a phenyl having 1 or 2 substituents selected from a halogen atom, a trihalogeno (C₁₋₆) alkyl and a C₁₋₆ alkyl, iii) naphthyl, or iv) a halogenophenyl-substituted C₁₋₆ alkyl; and R⁷ and R⁸ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₂₋₆ alkenyl, iv) a C₂₋₆ alkynyl, or v) a C₁₋₆ alkyl substituted by a di(C₁₋₆)alkoxyphenyl, or both form together with the adjacent nitrogen atom a nitrogen-containing monoheterocyclic group selected from morpholinyl, pyrrolidinyl, piperidyl and imidazolyl; provided that when both of R¹ and R² are hydrogen atom, Z² is oxygen atom and either one of R⁵ and R⁶ is i) a phenyl having 1 or 2 substituents selected from a halogen atom, a trihalogeno(C₁₋₆)alkyl and a C₁₋₆ alkyl, or ii) naphthyl.
4. A process according to claim 1, wherein R³ and R⁴ are both hydrogen atom; one of R⁵ and R⁶ is hydrogen atom and another is i) a C₃₋₈ cycloalkyl, ii) a phenyl having 1 or 2 substituents selected from a halogen atom, a trihalogeno (C₁₋₆) alkyl and a C₁₋₆ alkyl, or iii) naphthyl; and R⁷ and R⁸ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₂₋₆ alkenyl, or iv) a C₂₋₆ alkynyl, or both form together with the adjacent nitrogen atom piperidyl; provided that when both of R¹ and R² are hydrogen atom, Z² is oxygen atom and either one of R⁵ and R⁶ is i) a phenyl having 1 or 2 substituents selected from a halogen atom, a trihalogeno (C₁₋₆) alkyl and a C₁₋₆ alkyl, or ii) naphthyl.
5. A process according to claim 4, wherein X is a sulfur atom.

6. The process according to claim 5, wherein one of R⁵ and R⁶ is hydrogen atom and another is halogenophenyl or a trihalogeno(C₁₋₆)alkyl(phenyl, and R⁷ and R⁸ are the same or different and are each a C₁₋₆ alkyl.
7. A process according to claim 5, wherein one of R⁵ and R⁶ is hydrogen atom and another is chlorophenyl or trifluoromethylphenyl, and R⁷ and R⁸ are both methyl or ethyl.
8. A process according to claim 1, wherein the said derivative is 2-(4-chlorophenyl)-4-(diethylamino)acetyl-3,4-dihydro-2H-1,4-benzothiazine or a pharmaceutically acceptable salt thereof.
9. A process according to claim 1, wherein the said derivative is 3-(4-chlorophenyl)-1-(diethylamino)acetyl-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazine or a pharmaceutically acceptable salt thereof.
10. A process according to claim 1, wherein the said derivative is 1-[3-(dimethylamino)propyl]-3-(3-trifluoromethylphenyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-one or a pharmaceutically acceptable salt thereof.
11. A process for preparing a thiazine or oxazine derivative of the following formula [I]:



wherein R¹ and R² are both hydrogen atom or form a naphthalene ring together with the benzene ring; R³ and R⁴ are both hydrogen atom, or one of them is a halogen atom and another is hydrogen atom; X is sulfur atom or oxygen atom; R⁵ and R⁶ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₃₋₈ cycloalkyl, iv) a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, v) naphthyl, vi) a C₁₋₆ alkyl which is substituted by a phenyl or a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or vii) a sulfur containing monoheterocyclic group; one of Z¹ and Z² is oxygen atom and another is two hydrogen atoms; A is a C₁₋₆ alkylene; R⁷ and R⁸ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₂₋₆ alkenyl, iv) a C₂₋₆ alkynyl, or v) a C₁₋₆ alkyl which is substituted by a phenyl or a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or both form together with the adjacent nitrogen atom a nitrogen-containing monoheterocyclic group; provided that when both of R¹ and R² are hydrogen atom, Z² is oxygen atom and either one of R⁵ and R⁶ is a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, naphthyl or a sulfur-containing monoheterocyclic group, or a pharmaceutically acceptable salt thereof, which comprises the steps of


(a) reacting a compound of the formula:



wherein R¹, R², R³, R⁴, R⁵, R⁶, X and Z¹ are as defined above or a salt thereof with a compound of the formula:



wherein Y¹ and Y² are the same or different and are each a reactive residue, and A and Z² are as defined above, to give a compound of the formula:




15

wherein R¹, R², R³, R⁴, R⁵, R⁶, X, A, Z¹, Z² and Y¹ are as defined above, and then reacting the above compound [IV] with an amine compound of the formula:



25

wherein R⁷ and R⁸ are as defined above, or a salt thereof, or
(b) reacting the compound of the formula [II] or a salt thereof with a compound of the formula:




35

wherein Y³ is a reactive residue, and Z², A, R⁷ and R⁸ are as defined above, or
(c) in case of the compound [I] wherein A is ethylene, Z¹ is two hydrogen atom, and Z² is oxygen atom, reacting the compound of the formula [II] or a salt thereof with an acrylic acid compound of the formula:




wherein Y² is as defined above, to give a compound of the formula:



55

wherein R¹, R², R³, R⁴, R⁵, R⁶, and X are as defined above, and then reacting the above compound [VIII] with an amine compound [V], or a salt thereof, or
(d) in case of the compounds [I] wherein at least one of R⁷ and R⁸ is a C₁₋₈ alkyl, a C₂₋₈ alkenyl, a C₂₋₈ alkynyl, or a C₁₋₈ alkyl which is substituted by a phenyl or a phenyl having one or two substituents selected from a halogen

atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, reacting a compound of the formula:




15 wherein R¹, R², R³, R⁴, R⁵, R⁶, X, A, Z¹, and Z² are as defined above, and R⁷¹ is hydrogen atom, a C₁₋₆ alkyl, a C₂₋₆ alkenyl, a C₂₋₆ alkynyl, or a C₁₋₆ alkyl which is substituted by a phenyl or a phenyl having one or two substituents selected from a halogen atom, a trihalogen C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or a salt thereof with a compound of the formula:



25 wherein R⁸¹ is a C₁₋₆ alkyl, a C₂₋₆ alkenyl, a C₂₋₆ alkynyl, or a C₁₋₆ alkyl which is substituted by a phenyl or a phenyl having one or two substituents selected from a halogen atom, a trihalogeno C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, and Y⁴ is a reactive residue, optionally followed by converting the compound [I] in the free form into a pharmaceutically acceptable salt thereof.

12. A process as claimed in claim 11 wherein the derivative of formula [I] is produced using a compound of the formula



40 wherein X' is sulfur atom or oxygen atom; R⁵¹ and R⁶¹ are the same or different and are each i) hydrogen atom, ii) a C₁₋₆ alkyl, iii) a C₃₋₈ cycloalkyl, iv) a phenyl having one or two substituents selected from a halogen atom, a trihalogen C₁₋₆ alkyl, C₁₋₆ alkyl and a C₁₋₆ alkoxy, v) naphthyl, vi) a C₁₋₆ alkyl which is substituted by a phenyl or a phenyl having one or two substituents selected from a halogen atom, a trihalogen C₁₋₆ alkyl, a C₁₋₆ alkyl and a C₁₋₆ alkoxy, or vii) a sulfur-containing monoheterocyclic group; Z¹¹ is oxygen atom or is two hydrogen atoms; provided that when Z¹¹ is two hydrogen atoms and R⁵¹ and R⁶¹ are both hydrogen atom, X' is sulfur atom, or a salt thereof.


45 13. A process for producing a pharmaceutical composition wherein a compound of Formula [I] is prepared by the process of claim 11 or claim 12 and the resulting compound or pharmaceutically active salt thereof is admixed with a pharmaceutically acceptable carrier or diluent.

50 14. A process as claimed in any one of the preceding claims, wherein there is produced a medicament for the prophylaxis and treatment of ischemicencephalopathia and/or cerebral neurocyte dyscrasia.

Patentansprüche

Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

- 5 1. Thiazin- oder Oxazin-Derivat der allgemeinen Formel [I]:




20 in der R¹ und R² beide ein Wasserstoffatom sind oder zusammen mit dem Benzol-Ring einen Naphthalin-Ring bilden; R³ und R⁴ beide ein Wasserstoffatom sind oder ein Rest von diesen ein Halogenatom ist und der andere ein Wasserstoffatom ist; X ein Schwefelatom oder Sauerstoffatom ist; R⁵ und R⁶ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₃₋₈-Cycloalkyl, iv) ein Phenyl mit einem oder zwei Substituenten, ausgewählt aus einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, v) Naphthyl, vi) ein C₁₋₆-Alkyl, das mit einem Phenyl oder Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy substituiert ist, oder vii) eine schwefelhaltige monoheterocyclische Gruppe sind; einer der Reste Z¹ und Z² ein Sauerstoffatom ist und der andere zwei Wasserstoffatome ist; A C₁₋₆-Alkylen ist; R⁷ und R⁸ gleich oder verschieden sind, und jeweils i) ein C₁₋₆-Alkyl, ii) ein C₂₋₆-Alkenyl, iii) ein C₂₋₆-Alkynyl oder v) ein C₁₋₆-Alkyl, das durch ein Phenyl oder ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, substituiert ist, sind, oder beide zusammen mit dem benachbarten Stickstoffatom eine stickstoffhaltige monoheterocyclische Gruppe bilden; vorausgesetzt, daß wenn R¹ und R² beide ein Wasserstoffatom darstellen, Z² ein Sauerstoffatom ist, und einer der Reste R⁵ und R⁶ ein Phenyl mit einem oder zwei Substituenten, ausgewählt aus einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, ein Naphthyl oder eine schwefelhaltige monoheterocyclische Gruppe ist; oder ein pharmazeutisch akzeptables Salz desselben.

2. Verbindung nach Anspruch 1, in der R³ und R⁴ beide ein Wasserstoffatom sind; R⁵ und R⁶ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₃₋₈-Cycloalkyl, iv) ein Phenyl mit 1 oder 2 Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl und einem C₁₋₆-Alkyl, v) Naphthyl oder vi) Thienyl sind; und R⁷ und R⁸ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₂₋₆-Alkenyl oder iv) ein C₂₋₆-Alkynyl sind, oder beide zusammen mit dem benachbarten Stickstoffatom eine stickstoffhaltige monoheterocyclische Gruppe, ausgewählt unter Morpholinyl, Pyrrolidinyl und Piperidinyl, bilden; vorausgesetzt, daß wenn R¹ und R² beide ein Wasserstoffatom sind, Z² ein Sauerstoffatom ist und jeder der Reste R⁵ und R⁶ i) ein Phenyl mit 1 oder 2 Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl und einem C₁₋₆-Alkyl, ii) Naphthyl oder iii) Thienyl ist.

3. Verbindung nach Anspruch 1, in der einer der Reste R⁵ und R⁶ ein Wasserstoffatom ist und der andere i) ein C₃₋₈-Cycloalkyl, ii) ein Phenyl mit 1 oder 2 Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl und einem C₁₋₆-Alkyl, iii) ein Naphthyl oder iv) ein mit Halogenphenyl substituiertes C₁₋₆-Alkyl ist; und R⁷ und R⁸ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₂₋₆-Alkenyl, iv) ein C₂₋₆-Alkynyl oder v) ein C₁₋₆-Alkyl, das durch ein Di-(C₁₋₆)-alkoxyphenyl substituiert ist, darstellen oder beide zusammen mit dem benachbarten Stickstoffatom eine stickstoffhaltige monoheterocyclische Gruppe, ausgewählt aus Morpholinyl, Pyrrolidinyl, Piperidinyl und Imidazolyl bilden; vorausgesetzt, daß wenn R¹ und R² beide ein Wasserstoffatom sind, Z² ein Sauerstoffatom ist und einer der beiden Reste R⁵ und R⁶ i) ein Phenyl mit 1 oder 2 Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen(C₁₋₆)-alkyl und einem C₁₋₆-Alkyl, oder ii) ein Naphthyl ist.

4. Verbindung nach Anspruch 1, in der R³ und R⁴ beide Wasserstoffatome sind; einer der Reste R⁵ und R⁶ ein Wasserstoffatom ist und der andere i) ein C₃₋₈-Cycloalkyl, ii) ein Phenyl mit 1 oder 2 Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-(C₁₋₆)-alkyl und einem C₁₋₆-Alkyl, oder iii) Naphthyl ist; und R⁷ und R⁸ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₂₋₆-Alkenyl, oder iv) ein C₂₋₆-Alkynyl sind, oder beide zusammen mit dem benachbarten Stickstoffatom Piperidyl bilden; vorausgesetzt, daß wenn R¹ und R² beide Wasserstoffatome sind, Z² ein Sauerstoffatom ist und irgendeiner der beiden Reste R⁵ und R⁶ i) ein Phenyl mit 1 oder 2 Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-(C₁₋₆)-alkyl und einem C₁₋₆-Alkyl, oder ii) Naphthyl ist.
5. Verbindung nach Anspruch 4, in der X ein Schwefelatom ist.
6. Verbindung nach Anspruch 5, in der einer der Reste R⁵ und R⁶ ein Wasserstoffatom ist und der andere ein Halogenphenyl oder ein Trihalogen-(C₁₋₆)-alkylphenyl ist, und R⁷ und R⁸ gleich oder verschieden sind und jeweils C₁₋₆-Alkyl sind.
7. Verbindung nach Anspruch 5, in der einer der Reste R⁵ und R⁶ ein Wasserstoffatom ist und der andere Chlorphenyl oder Trifluormethylphenyl ist, und R⁷ und R⁸ beide Methyl oder Ethyl sind.
8. 2-(4-Chlorphenyl)-4-(diethylamino)acetyl-3,4-dihydro-2H-1,4-benzothiazin oder ein pharmazeutisch akzeptables Salz desselben.
9. 3-(4-Chlorphenyl)-1-(diethylamino)acetyl-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazin oder ein pharmazeutisch akzeptables Salz desselben.
10. 1-[3-(Dimethylamino)propyl]-3-(3-trifluormethylphenyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-on oder ein pharmazeutisch akzeptables Salz desselben.
11. Pharmazeutische Zusammensetzung, die eine Menge eines Thiazins oder Oxazins nach einem der vorangehenden Ansprüche im Gemisch mit einem pharmazeutisch akzeptablen Trägerstoff oder einem Verdünnungsmittel enthält.
12. Verfahren zur Herstellung eines Thiazin- oder Oxazin-Derivats der folgenden Formel [I]:




in der R¹ und R² beide ein Wasserstoffatom darstellen oder zusammen mit dem Benzol-Ring einen Naphthalin-Ring bilden; R³ und R⁴ beide ein Wasserstoffatom darstellen oder einer dieser Reste ein Halogenatom ist und der andere ein Wasserstoffatom ist; X ein Schwefelatom oder Sauerstoffatom ist; R⁵ und R⁶ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₃₋₈-Cycloalkyl, iv) ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, v) Naphthyl, vi) ein C₁₋₆-Alkyl, das mit einem Phenyl oder einem Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, substituiert ist, oder vii) eine schwefelhaltige monoheterocyclische Gruppe sind; einer Reste der Z¹ und Z² ein Sauerstoffatom ist und der andere zwei Wasserstoffatome darstellt; A ein C₁₋₆-Alkyl ist; R⁷ und R⁸ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₂₋₆-Alkenyl, iv) ein C₂₋₆-Alkynyl oder v) ein C₁₋₆-Alkyl, das durch Phenyl oder ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, substituiert ist, sind, oder beide zusammen mit dem benachbarten Stickstoffatom eine stickstoffhaltige monoheterocyclische Gruppe bilden; vorausgesetzt, daß wenn R¹ und R² beide Wasserstoffatome sind, Z² ein Sauerstoffatom ist und einer der Reste R⁵ und R⁶ Phenyl mit einem oder zwei Substituenten, ausgewählt aus einem Halogenatom, einem Trihalogen-

C₁₋₆-alkyl, in m C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, Naphthyl oder eine schwefelhaltige monoheterocyclische Gruppe ist;
 oder eines pharmazeutisch akzeptablen Salzes desselben,
 das die folgenden Schritte umfaßt:

5

(a) Umsetzen einer Verbindung der Formel:

10




[II]

15

in der R¹, R², R³, R⁴, R⁵, R⁶, X und Z¹ wie oben definiert sind, oder eines Salzes derselben mit einer Verbindung der Formel:

20




[III]

wobei Y¹ und Y² gleich oder verschieden sind und jeweils einen reaktiven Rest darstellen, und A und Z² wie oben definiert sind,

25

wobei eine Verbindung der Formel:

30




[IV]

35

40

erhalten wird, in der R¹, R², R³, R⁴, R⁵, R⁶, X, A, Z¹, Z² und Y¹ wie oben definiert sind, und danach Umsetzen der obigen Verbindung [IV] mit einer Amin-Verbindung der Formel:

45




[V]

50

worin R⁷ und R⁸ wie oben definiert sind, oder einem Salz derselben, oder

55

(b) Umsetzen der Verbindung der Formel [II] oder eines Salzes derselben mit einer Verbindung der Formel:




wobei Y^3 ein reaktiver Rest ist, und Z^2 , A, R^7 und R^8 wie oben definiert sind, oder

(c) im Fall der Verbindung [I], in der A Ethylen ist, Z^1 zwei Wasserstoffatome darstellt und Z^2 Sauerstoff ist, Umsetzen der Verbindung der Formel [II] oder eines Salzes derselben mit einer Acrylsäure-Verbindung der Formel:




wobei Y^2 wie oben definiert ist, unter Erhalt einer Verbindung der Formel:



in der R^1 , R^2 , R^3 , R^4 , R^5 , R^6 und X wie oben definiert sind;

und dann Umsetzen der obigen Verbindung [VIII] mit einer Amin-Verbindung [V] oder einem Salz derselben, oder (d) im Fall der Verbindungen [I], in denen mindestens einer der Rest R^7 und R^8 ein C_{1-6} -Alkyl, ein C_{2-6} -Alkenyl, ein C_{2-6} -Alkynyl oder ein C_{1-6} -Alkyl, das mit einem Phenyl oder einem Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen- C_{1-6} -alkyl, einem C_{1-6} -Alkyl und einem C_{1-6} -Alkoxy, substituiert ist, darstellt,

Umsetzen einer Verbindung der Formel:




in der R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , X, A, Z^1 und Z^2 wie oben definiert sind, und R^{71} ein Wasserstoffatom, ein C_{1-6} -Alkyl, ein C_{2-6} -Alkenyl, ein C_{2-6} -Alkynyl oder ein C_{1-6} -Alkyl, das durch ein Phenyl oder ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen- C_{1-6} -alkyl, einem C_{1-6} -Alkyl und einem C_{1-6} -Alkoxy, substituiert ist, darstellt; oder einem Salz derselben mit einer Verbindung der Formel:



in der R^{81} ein C_{1-6} -Alkyl, ein C_{2-6} -Alkenyl, ein C_{2-6} -Alkynyl oder ein C_{1-6} -Alkyl, das durch ein Phenyl oder ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen- C_{1-6} -alkyl, einem C_{1-6} -Alkyl und einem C_{1-6} -Alkoxy substituiert ist, darstellt, und Y^4 ein reaktiver Rest ist,

wahlweise gefolgt von einer Umwandlung der Verbindung [I] in freier Form in ein pharmazeutisch akzeptables Salz derselben.

13. Verbindung der Formel:




in der X' ein Schwefelatom oder ein Sauerstoffatom ist; R⁵¹ und R⁶¹ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₃₋₈-Cycloalkyl, iv) ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, v) Naphthyl, vi) ein C₁₋₆-Alkyl, das durch ein Phenyl oder ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einer C₁₋₆-Alkoxy, substituiert ist, oder vii) eine schwefelhaltige monoheterocyclische Gruppe sind; Z¹¹ ein Sauerstoffatom oder zwei Wasserstoffatome ist, vorausgesetzt, daß wenn Z¹¹ zwei Wasserstoffatome darstellt und R⁵¹ und R⁶¹ beide Wasserstoffatome sind, X' ein Schwefelatom ist; oder ein Salz derselben.

14. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 12 in der Herstellung eines Arzneimittels zur Prophylaxe und Behandlung von ischämischer Enzephalopathie und/oder Dyscrasie zerebraler Neurozyten.

Patentansprüche für folgende Vertragsstaaten : ES, GR

1. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, das ein Vermischen eines Thiazin- oder Oxazin-Derivats der folgenden Formel [I]:




in der R¹ und R² beide Wasserstoffatome sind oder zusammen mit dem Benzol-Ring einen Naphthalin-Ring bilden; R³ und R⁴ beide Wasserstoffatome sind oder einer dieser Reste ein Halogenatom und der andere ein Wasserstoffatom ist; X ein Schwefelatom oder Sauerstoffatom ist; R⁵ und R⁶ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₃₋₈-Cycloalkyl, iv) ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, v) Naphthyl, vi) ein C₁₋₆-Alkyl, das durch ein Phenyl oder ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, substituiert ist, oder vii) eine schwefelhaltige monoheterocyclische Gruppe sind; einer der Reste Z¹ und Z² ein Sauerstoffatom ist und der andere zwei Wasserstoffatome darstellt; A ein C₁₋₆-Alkyl; R⁷ und R⁸ gleich oder verschieden sind, und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₂₋₆-Alkenyl, iv) ein C₂₋₆-Alkyl oder v) ein C₁₋₆-Alkyl, das durch ein Phenyl oder ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, substituiert ist, sind, oder beide zusammen mit dem benachbarten Stickstoffatom eine stickstoffhaltige monoheterocyclische Gruppe bilden; vorausgesetzt, daß wenn R¹ und R² beide ein Wasserstoffatom sind, Z² ein Sauerstoffatom ist, und einer der Reste R⁵ und R⁶ ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-

Alkyl und einem C₁₋₆-Alkoxy, Naphthyl oder eine schwefelhaltige monoheterocyclische Gruppe ist; oder eines pharmazeutisch akzeptablen Salzes desselben mit einem pharmazeutisch akzeptablen Trägerstoff oder Verdünnungsmittel umfaßt.


- 5 2. Verfahren nach Anspruch 1, wobei R³ und R⁴ beide Wasserstoffatome sind; R⁵ und R⁶ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₃₋₈-Cycloalkyl, iv) ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl und einem C₁₋₆-Alkyl, v) Naphthyl oder vi) Thienyl sind; und R⁷ und R⁸ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₂₋₆-Alkenyl oder iv) ein C₂₋₆-Alkynyl sind, oder beide zusammen mit dem benachbarten Stickstoffatom eine stickstoffhaltige monoheterocyclische Gruppe, ausgewählt unter Morpholinyl, Pyrrolidinyl und Piperidyl, bilden; vorausgesetzt, daß wenn R¹ und R² beide Wasserstoffatome sind, Z² ein Sauerstoffatom ist und einer der beiden Reste R⁵ und R⁶ i) ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl und einem C₁₋₆-Alkyl, ii) Naphthyl oder iii) Thienyl ist.
- 10 3. Verfahren nach Anspruch 1, wobei einer der Reste R⁵ und R⁶ ein Wasserstoffatom ist und der andere i) ein C₃₋₈-Cycloalkyl, ii) ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl und einem C₁₋₆-Alkyl, iii) Naphthyl oder iv) ein Halogenphenyl-substituiertes C₁₋₆-Alkyl ist; und R⁷ und R⁸ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₂₋₆-Alkenyl, iv) ein C₂₋₆-Alkynyl oder v) ein C₁₋₆-Alkyl, das durch ein Di-(C₁₋₆)-alkoxyphenyl substituiert ist, ist oder beide zusammen mit dem benachbarten Stickstoffatom eine stickstoffhaltige monoheterocyclische Gruppe, ausgewählt unter Morpholinyl, Pyrrolidinyl, Piperidinyl und Imidazolyl bilden; vorausgesetzt, daß wenn R¹ und R² beide Wasserstoffatome sind, Z² ein Sauerstoffatom ist und einer der beiden Reste R⁵ und R⁶ i) ein Phenyl, mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-(C₁₋₆)-alkyl und einem C₁₋₆-Alkyl, oder ii) Naphthyl ist.
- 15 4. Verfahren nach Anspruch 1, wobei R³ und R⁴ beide Wasserstoffatome sind; einer der Reste R⁵ und R⁶ ein Wasserstoffatom ist und der andere i) ein C₃₋₈-Cycloalkyl, ii) ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-(C₁₋₆)-alkyl und einem C₁₋₆-Alkyl, oder iii) Naphthyl ist; und R⁷ und R⁸ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₂₋₆-Alkenyl, oder iv) ein C₂₋₆-Alkynyl sind, oder beide zusammen mit dem benachbarten Stickstoffatom Piperidyl bilden; vorausgesetzt, daß wenn R¹ und R² beide Wasserstoffatome sind, Z² ein Sauerstoffatom ist, und einer der beiden Reste R⁵ und R⁶ i) ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-(C₁₋₆)-alkyl und einem C₁₋₆-Alkyl, oder ii) Naphthyl ist.
- 20 5. Verfahren nach Anspruch 4, wobei X ein Schwefelatom ist.
- 25 6. Verfahren nach Anspruch 5, wobei einer der Reste R⁵ und R⁶ ein Wasserstoffatom ist und der andere ein Halogenphenyl oder ein Trihalogen-(C₁₋₆)-alkylphenyl ist, und R⁷ und R⁸ gleich oder verschieden sind und jeweils ein C₁₋₆-Alkyl sind.
- 30 7. Verfahren nach Anspruch 5, wobei einer der Reste R⁵ und R⁶ ein Wasserstoffatom ist und der andere Chlorphenyl oder Trifluormethylphenyl ist, und R⁷ und R⁸ beide Methyl oder Ethyl sind.
- 35 8. Verfahren nach Anspruch 1, in dem das genannte Derivat 2-(4-Chlorphenyl)-4-(diethylamino)acetyl-3,4-dihydro-2H-1,4-benzothiazin oder ein pharmazeutisch akzeptables Salz desselben ist.
- 40 9. Verfahren nach Anspruch 1, in dem das genannte Derivat 3-(4-Chlorphenyl)-1-(diethylamino)acetyl-2,3-dihydro-1H-naphtho[2,1-b][1,4]thiazin oder ein pharmazeutisch akzeptables Salz desselben ist.
- 45 10. Verfahren nach Anspruch 1, in dem das Derivat 1-[3-Dimethylamino]propyl]-3-(3-trifluormethylphenyl)-1H-naphtho[2,1-b][1,4]thiazin-2(3H)-on oder ein pharmazeutisch akzeptables Salz desselben ist.
- 50
- 55

11. Verfahren zur Herstellung eines Thiazins- oder Oxazin-Derivats der folgenden Formel [I]:



15 in der R¹ und R² beide Wasserstoffatome sind oder zusammen mit dem Benzol-Ring einen Naphthalin-Ring bilden; R³ und R⁴ beide Wasserstoffatome darstellen oder einer dieser Reste ein Halogenatom ist und der andere ein Wasserstoffatom ist; X ein Schwefelatom oder Sauerstoffatom ist; R⁵ und R⁶ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₃₋₈-Cycloalkyl, iv) ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, v) Naphthyl, vi) ein C₁₋₆-Alkyl, das durch ein Phenyl oder ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, substituiert ist, oder vii) eine schwefelhaltige monoheterocyclische Gruppe sind; einer der Reste der Z¹ und Z² ein Sauerstoffatom ist und der andere zwei Wasserstoffatome darstellt; A ein C₁₋₆-Alkyl ist; R⁷ und R⁸ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₂₋₆-Alkenyl, iv) ein C₂₋₆-Alkynyl oder v) ein C₁₋₆-Alkyl, das durch ein Phenyl oder ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, substituiert ist, sind, oder zusammen mit dem benachbarten Stickstoffatom eine stickstoffhaltige monoheterocyclische Gruppe bilden; vorausgesetzt, daß wenn R¹ und R² beide Wasserstoffatome sind, Z² ein Sauerstoffatom ist und einer der Reste R⁵ und R⁶ ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, Naphthyl oder eine schwefelhaltige monoheterocyclische Gruppe ist; oder eines pharmazeutisch akzeptablen Salzes desselben, das die folgenden Schritte umfaßt:


35 (a) Umsetzen einer Verbindung der Formel:



in der R¹, R², R³, R⁴, R⁵, R⁶, X und Z¹ wie oben definiert sind, oder eines Salzes derselben mit einer Verbindung der Formel:




worin Y¹ und Y² gleich oder verschieden sind und jeweils einen reaktiven Rest darstellen, und A und Z² wie oben definiert sind, unter Erhalt einer Verbindung der Formel:



15 in der R¹, R², R³, R⁴, R⁵, R⁶, X, A, Z¹, Z² und Y¹ wie oben definiert sind, und dann Umsetzen der obigen Verbindung [IV] mit einer Amin-Verbindung der Formel:




25 in der R⁷ und R⁸ wie oben definiert sind, oder einem Salz derselben, oder
(b) Umsetzen der Verbindung der Formel [II] oder eines Salzes derselben mit einer Verbindung der Formel:



35 in der Y³ ein reaktiver Rest ist, und Z², A, R⁷ und R⁸ wie oben definiert sind, oder
(c) im Fall der Verbindung [I], in der A Ethylen ist, Z¹ zwei Wasserstoffatome darstellt, und Z² ein Sauerstoffatom ist, Umsetzen der Verbindung der Formel [II] oder eines Salzes derselben mit einer Acrylsäure-Verbindung der Formel:




worin Y² wie oben definiert ist, unter Erhalt einer Verbindung der Formel:



55 in der R¹, R², R³, R⁴, R⁵, R⁶ und X wie oben definiert sind;
und dann Umsetzen der obigen Verbindung [VIII] mit einer Amin-Verbindung [V] oder eines Salzes derselben;
oder

(d) im Fall der Verbindungen [I], in denen mindestens einer der Rest R⁷ und R⁸ ein C₁₋₆-Alkyl, ein C₂₋₆-Alkenyl, in C₂₋₆-Alkyl oder in C₁₋₆-Alkyl, das durch ein Phenyl oder ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, substituiert ist, darstellt, Umsetzen einer Verbindung der Formel:




worin R¹, R², R³, R⁴, R⁵, R⁶, X, A, Z¹ und Z² wie oben definiert sind, und R⁷¹ ein Wasserstoffatom, ein C₁₋₆-Alkyl, ein C₂₋₆-Alkenyl, ein C₂₋₆-Alkyl oder ein C₁₋₆-Alkyl, das durch ein Phenyl oder ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, substituiert ist, darstellt; oder einem Salz derselben mit einer Verbindung der Formel:



in der R⁸¹ ein C₁₋₆-Alkyl, ein C₂₋₆-Alkenyl, ein C₂₋₆-Alkyl oder ein C₁₋₆-Alkyl, das durch ein Phenyl oder ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy substituiert ist, darstellt, und Y⁴ ein reaktiver Rest ist, wahlweise gefolgt von einer Umwandlung der Verbindung [I] in freier Form in ein pharmazeutisch akzeptables Salz derselben.

12. Verfahren nach Anspruch 11, in dem das Derivat der Formel [I] unter Verwendung einer Verbindung der folgenden Formel:




in der X' ein Schwefelatom oder Sauerstoffatom ist; R⁵¹ und R⁶¹ gleich oder verschieden sind und jeweils i) ein Wasserstoffatom, ii) ein C₁₋₆-Alkyl, iii) ein C₃₋₆-Cycloalkyl, iv) ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, v) Naphthyl, vi) ein C₁₋₆-Alkyl, das durch ein Phenyl oder ein Phenyl mit einem oder zwei Substituenten, ausgewählt unter einem Halogenatom, einem Trihalogen-C₁₋₆-alkyl, einem C₁₋₆-Alkyl und einem C₁₋₆-Alkoxy, substituiert ist, oder vii) eine schwefelhaltige monoheterocyclische Gruppe sind; Z¹¹ ein Sauerstoffatom ist oder zwei Wasserstoffatome darstellt; vorausgesetzt, daß wenn Z¹¹ zwei Wasserstoffatome darstellt und R⁵¹ und R⁶¹ beide Wasserstoffatome sind, X' ein Schwefelatom ist; oder eines Salzes desselben hergestellt wird.

13. Verfahren zur Herstellung pharmazeutischen Zusammensetzung, wobei eine Verbindung der Formel [I] nach dem Verfahren gemäß 11 oder Anspruch 12 hergestellt wird, und die resultierende Verbindung oder das pharmazeutisch aktive Salz derselben mit einem pharmazeutisch akzeptablen Trägerstoff oder Verdünnungsmittel vermischt wird.
14. Verfahren nach einem der vorangehenden Ansprüche, in dem ein Arzneimittel zur Prophylaxe und Behandlung von ischämischer Encephalopathie und/oder Dyscrasie zerebraler Neurozyten hergestellt wird.

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Dérivé de thiazine ou d'oxazine de formule [I] suivante :




dans laquelle R¹ et R² représentent chacun un atome d'hydrogène ou forment un noyau naphthalène avec le noyau benzène ; R³ et R⁴ représentent chacun un atome d'hydrogène, ou bien l'un d'entre eux représente un atome d'halogène et l'autre représente un atome d'hydrogène ; X représente un atome de soufre ou un atome d'oxygène ; R⁵ et R⁶ sont identiques ou différents et représentent chacun i) un atome d'hydrogène, ii) un groupe alkyle en C₁₋₆, iii) un groupe cycloalkyle en C₃₋₈, iv) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆), un groupe alkyle en C₁₋₆ et un groupe alcoxy en C₁₋₆, v) un groupe naphthyle, vi) un groupe alkyle qui porte comme substituant un groupe phényle ou un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆), un groupe alkyle en C₁₋₆ et un groupe alcoxy en C₁₋₆, ou vii) un groupe monohétérocyclique contenant un atome de soufre ; l'un parmi Z¹ et Z² représente un atome d'oxygène et l'autre représente deux atomes d'hydrogène ; A représente un groupe alkylène en C₁₋₆ ; R⁷ et R⁸ sont identiques ou différents et représentent chacun i) un atome d'hydrogène, ii) un groupe alkyle en C₁₋₆, iii) un groupe alcényle en C₂₋₆, iv) un groupe alcynyle en C₂₋₆, ou v) un groupe alkyle en C₁₋₆ qui porte comme substituant un groupe phényle ou un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆), un groupe alkyle en C₁₋₆ et un groupe alcoxy en C₁₋₆, ou forment ensemble avec l'atome d'azote adjacent un groupe monohétérocyclique contenant un atome d'azote ; à condition que lorsque R¹ et R² représentent chacun un atome d'hydrogène, Z² représente un atome d'oxygène et l'un parmi R⁵ et R⁶ représente un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(C₁₋₆), un groupe alkyle en C₁₋₆ et un groupe alcoxy en C₁₋₆, un groupe naphthyle ou un groupe monohétérocyclique contenant un atome de soufre, ou l'un de ses sels acceptable du point de vue pharmaceutique.

2. Composé selon la revendication 1, dans lequel R³ et R⁴ représentent chacun un atome d'hydrogène ; R⁵ et R⁶ sont identiques ou différents et représentent chacun i) un atome d'hydrogène, ii) un groupe alkyle en C₁₋₆, iii) un groupe cycloalkyle en C₃₋₈, iv) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆) et un groupe alkyle en C₁₋₆, v) un groupe naphthyle ou vi) un groupe thiényle ; et R⁷ et R⁸ sont identiques ou différents et représentent chacun i) un atome d'hydrogène, ii) un groupe alkyle en C₁₋₆, iii) un groupe alcényle en C₂₋₆ ou iv) un groupe alcynyle en C₂₋₆, ou forment ensemble avec l'atome d'azote adjacent un groupe monohétérocyclique contenant un atome d'azote choisi parmi les groupes morpholinyle, pyrrolidinyle et pipéridinyle ; à condition que lorsque R¹ et R² représentent chacun un atome d'hydrogène, Z² représente un atome d'oxygène et l'un parmi R⁵ et R⁶ représente i) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆) et un groupe alkyle en C₁₋₆, ii) un groupe naphthyle ou iii) un groupe thiényle.
3. Composé selon la revendication 1, dans lequel l'un parmi R⁵ et R⁶ représente un atome d'hydrogène et l'autre représente i) un groupe cycloalkyle en C₃₋₈, ii) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆) et un groupe alkyle, iii) un groupe naphthyle, ou iv) un groupe alkyle en C₁₋₆ portant comme substituant un groupe halogénophényle ; et R⁷ et R⁸ sont identiques ou différents et représentent chacun i) un atome d'hydrogène, ii) un groupe alkyle en C₁₋₆, iii) un groupe alcényle en C₂₋₆, iv) un groupe alcynyle en C₂₋₆, ou v) un groupe alkyle en C₁₋₆ qui porte comme substituant un groupe di(alcoxy en C₁₋₆)phényle ou forment ensemble avec l'atome d'azote adjacent un groupe monohétérocyclique contenant un atome d'azote choisi parmi les groupes morpholinyle, pyrrolidinyle et pipéridinyle et imidazolyle ; à condition que

lorsque R¹ et R² représentent chacun un atome d'hydrogène, Z² représente un atome d'oxygène et l'un parmi R⁵ et R⁶ représente i) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆) et un groupe alkyle en C₁₋₆, ou ii) un groupe naphthyle.


4. Composé selon la revendication 1, dans lequel R³ et R⁴ représentent chacun un atome d'hydrogène ; un parmi R⁵ et R⁶ représente un atome d'hydrogène et l'autre représente i) un groupe cycloalkyle en C₃₋₈, ii) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆) et un groupe alkyle C₁₋₆, ou iii) un groupe naphthyle ; et R⁷ et R⁸ sont identiques ou différents et représentent chacun i) un atome d'hydrogène, ii) un groupe alkyle en C₁₋₆, iii) un groupe alcényle en C₂₋₆, ou iv) un groupe alcynyle en C₂₋₆, ou forment ensemble avec l'atome d'azote adjacent un groupe pipéridyle ; à condition que lorsque R¹ et R² représentent chacun un atome d'hydrogène, Z² représente un atome d'oxygène et l'un parmi R⁵ et R⁶ représente i) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆) et un groupe alkyle en C₁₋₆, ou ii) un groupe naphthyle.
5. Composé selon la revendication 4, dans lequel X représente un atome de soufre.
6. Composé selon la revendication 5, dans lequel l'un parmi R⁵ et R⁶ représente un atome d'hydrogène et l'autre représente un groupe halogénophényle ou un groupe trihalogéno(alkyle en C₁₋₆)phényle, et R⁷ et R⁸ sont identiques ou différents et représentent chacun un groupe alkyle en C₁₋₆.
7. Composé selon la revendication 5, dans lequel l'un parmi R⁵ et R⁶ représente un atome d'hydrogène et l'autre représente un groupe chlorophényle ou trifluorométhylphényle, et R⁷ et R⁸ représentent chacun un groupe méthyle ou éthyle.
8. 2-(4-Chlorophényl)-4-(diéthylamino)acétyl-3,4-dihydro-2H-1,4-benzothiazine ou l'un de ses sels acceptables du point de vue pharmaceutique.
9. 3-(4-Chlorophényl)-1-(diéthylamino)acétyl-2,3-dihydro-1H-naphto[2,1-b][1,4]thiazine ou l'un de ses sels acceptables du point de vue pharmaceutique.
10. 1-[3-Diméthylamino)propyl]-3-(3-trifluorométhyl-phényl)-1H-naphto[2,1-b][1,4]thiazin-2(3H)-one ou l'un de ses sels acceptables du point de vue pharmaceutique.
11. Composition pharmaceutique qui comprend une quantité d'une thiazine ou d'une oxazine telle que revendiquée dans l'une quelconque des revendications précédentes en mélange avec un véhicule ou un diluant acceptable du point de vue pharmaceutique.
12. Procédé de préparation d'un dérivé de thiazine ou d'oxazine de formule [I] suivante :



dans laquelle R¹ et R² représentent chacun un atome d'hydrogène ou forment un noyau naphthalène avec le noyau benzène ; R³ et R⁴ représentent chacun un atome d'hydrogène, ou bien l'un d'entre eux représente un atome d'halogène et l'autre représente un atome d'hydrogène ; X représente un atome de soufre ou un atome d'oxygène ; R⁵ et R⁶ sont identiques ou différents et représentent chacun i) un atome d'hydrogène, ii) un groupe alkyle en C₁₋₆, iii) un groupe cycloalkyle en C₃₋₈, iv) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆), un groupe alkyle en C₁₋₆ et un groupe alcoxy en C₁₋₆, v) un groupe naphthyle, vi) un groupe alkyle qui porte comme substituant un groupe phényle ou un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆), un

groupe alkyle en C₁₋₆ et un groupe alcoxy en C₁₋₆, ou vii) un groupe monohétérocyclique contenant un atome de soufre ; l'un parmi Z¹ et Z² représente un atome d'oxygène et l'autre représente deux atomes d'hydrogène ; A représente un groupe alkylène en C₁₋₆ ; R⁷ et R⁸ sont identiques ou différents et représentent chacun i) un atome d'hydrogène, ii) un groupe alkyle en C₁₋₆, iii) un groupe alcényle en C₂₋₆, iv) un groupe alcynyle en C₂₋₆, ou v) un groupe alkyle en C₁₋₆ qui porte comme substituant un groupe phényle ou un groupe phényl portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆), un groupe alkyle en C₁₋₆ et un groupe alcoxy en C₁₋₆, ou forment ensemble avec l'atome d'azote adjacent un groupe monohétérocyclique contenant un atome d'azote ; à condition que lorsque R¹ et R² représentent chacun un atome d'hydrogène, Z² représente un atome d'oxygène et l'un parmi R⁵ et R⁶ représente un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(C₁₋₆), un groupe alkyle en C₁₋₆ et un groupe alcoxy en C₁₋₆, un groupe naphthyle ou un groupe monohétérocyclique contenant un atome de soufre, ou l'un de ses sels acceptable du point de vue pharmaceutique qui comprend les étapes consistant


(a) à faire réagir un composé de formule :



dans lequel R¹, R², R³, R⁴, R⁵, R⁶ et X et Z¹ sont tels que définis ci-dessus ou un sel de celui-ci avec un composé de formule :



dans laquelle Y¹ et Y² sont identiques ou différents et représentent chacun un résidu réactif, et A et Z² sont tels que définis ci-dessus, pour obtenir un composé de formule :




dans lequel R¹, R², R³, R⁴, R⁵, R⁶, X, A, Z¹, Z² et Y¹ sont tels que définis ci-dessus, puis à faire réagir le composé [IV] ci-dessus avec un composé amine de formule :



dans laquelle R⁷ et R⁸ sont tels que définis ci-dessus ou avec l'un de ses sels, ou

(b) à faire réagir le composé de formule [II] ou l'un de ses sels avec un composé de formule :




dans lequel Y^3 représente un résidu réactif et Z^2 , A, R^7 et R^8 sont tels que définis ci-dessus, ou

(c) dans le cas où dans le composé [I] A représente un groupe éthylène, Z^1 représente deux atomes d'hydrogène, et Z^2 représente un atome d'oxygène, à faire réagir le composé de formule [II] ou l'un de ses sels avec un composé d'acide acrylique de formule :




dans lequel Y^2 est tel que défini ci-dessus, pour obtenir un composé de formule :



dans laquelle R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , et X sont tels que définis ci-dessus, puis à faire réagir ensuite le composé de formule [VIII] ci-dessus avec un composé amine [V], ou l'un de ses sels, ou

(d) dans le cas où dans les composés [I] au moins l'un parmi R^7 et R^8 représente un groupe alkyle en C_{1-6} , un groupe alcényle en C_{2-6} , un groupe alcynyle en C_{2-6} , ou un groupe alkyle en C_{1-6} qui porte comme substituant un groupe phényle ou un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C_{1-6}), un groupe alkyle en C_{1-6} et un groupe alcoxy en C_{1-6} , à faire réagir un composé de formule :



dans laquelle R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , X, A, Z^1 et Z^2 sont tels que définis ci-dessus, et R^7 représente un atome d'hydrogène, un groupe alkyle en C_{1-6} , un groupe alcényle en C_{2-6} , un groupe alcynyle en C_{2-6} , ou un groupe alkyle en C_{1-6} portant comme substituant un groupe phényle ou un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C_{1-6}), un groupe alkyle en C_{1-6} et un groupe alcoxy en C_{1-6} , ou l'un de ses sels avec un composé de formule :




dans lequel R^{81} représente un groupe alkyle en C_{1-6} , un groupe alcényle en C_{2-6} , un groupe alcynyle en C_{2-6} , ou un groupe alkyle en C_{1-6} portant comme substituant un groupe phényle ou un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C_{1-6}), un groupe

- et un groupe alcoxy en C₁₋₆, ou forment ensemble avec l'atome d'azote adjacent un groupe monohétérocyclique contenant un atome d'azote ; à condition que lorsque R¹ et R² représentent chacun un atome d'hydrogène, Z² représente un atome d'oxygène et l'un parmi R⁵ et R⁶ représente un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(C₁₋₆), un groupe alkyle en C₁₋₆ et un groupe alcoxy en C₁₋₆, un group naphthyle ou un groupe monohétérocyclique contenant un atome de soufre, ou l'un de ses sels acceptable du point de vue pharmaceutique, avec un véhicule ou un diluant acceptable du point de vue pharmaceutique.
2. Procédé selon la revendication 1, dans lequel R³ et R⁴ représentent chacun un atome d'hydrogène ; R⁵ et R⁶ sont identiques ou différents et représentent chacun i) un atome d'hydrogène, ii) un groupe alkyle en C₁₋₆, iii) un groupe cycloalkyle en C₃₋₈, iv) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆) et un groupe alkyle en C₁₋₆, v) un groupe naphthyle ou vi) un groupe thiényl ; et R⁷ et R⁸ sont identiques ou différents et représentent chacun i) un atome d'hydrogène, ii) un groupe alkyle en C₁₋₆, iii) un groupe alcényle en C₂₋₆ ou iv) un groupe alcynyle en C₂₋₆, ou forment ensemble avec l'atome d'azote adjacent un groupe monohétérocyclique contenant un atome d'note choisi parmi les groupes morpholinyle, pyrrolidinyle et pipéridyle ; à condition que lorsque R¹ et R² représentent chacun un atome d'hydrogène, Z² représente un atome d'oxygène et l'un parmi R⁵ et R⁶ représente i) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆) et un groupe alkyle en C₁₋₆, ii) un groupe naphthyle ou iii) un groupe thiényl.
 3. Procédé selon la revendication 1, dans lequel l'un parmi R⁵ et R⁶ représente un atome d'hydrogène et l'autre représente i) un groupe cycloalkyle en C₃₋₈, ii) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆) et un groupe alkyle, iii) un groupe naphthyle, ou iv) un groupe alkyle en C₁₋₆ portant comme substituant un groupe halogénophényle ; et R⁷ et R⁸ sont identiques ou différents et représentent chacun i) un atome d'hydrogène, ii) un groupe alkyle en C₁₋₆, iii) un groupe alcényle en C₂₋₆, iv) un groupe alcynyle en C₂₋₆, ou v) un groupe alkyle en C₁₋₆ portant comme substituant un groupe di(alcoxy en C₁₋₆)phényle ou forment ensemble avec l'atome d'azote adjacent un groupe monohétérocyclique contenant un atome d'azote choisi parmi les groupes morpholinyle, pyrrolidinyle et pipéridinyle et imidazolyle ; à condition que lorsque R¹ et R² représentent chacun un atome d'hydrogène, Z² représente un atome d'oxygène et l'un parmi R⁵ et R⁶ représente i) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆) et un groupe alkyle en C₁₋₆, ou ii) un groupe naphthyle.
 4. Procédé selon la revendication 1, dans lequel R³ et R⁴ représente chacun un atome d'hydrogène ; l'un parmi R⁵ et R⁶ représente un atome d'hydrogène et l'autre représente i) un groupe cycloalkyle en C₃₋₈, ii) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆) et un groupe alkyle C₁₋₆, ou iii) un groupe naphthyle ; et R⁷ et R⁸ sont identiques ou différents et représentent chacun i) un atome d'hydrogène, ii) un groupe alkyle en C₁₋₆, iii) un groupe alcényle en C₂₋₆, ou iv) un groupe alcynyle en C₂₋₆, ou forment ensemble avec l'atome d'azote adjacent un groupe pipéridyle ; à condition que lorsque R¹ et R² représentent chacun un atome d'hydrogène, Z² représente un atome d'oxygène et l'un parmi R⁵ et R⁶ représente i) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆) et un groupe alkyle en C₁₋₆, ou ii) un groupe naphthyle.
 5. Procédé selon la revendication 4, dans lequel X représente un atome de soufre.
 6. Procédé selon la revendication 5, dans lequel l'un parmi R⁵ et R⁶ représente un atome d'hydrogène et l'autre représente un groupe halogénophényle ou un groupe trihalogéno(alkyle en C₁₋₆)phényle, et R⁷ et R⁸ sont identiques ou différents et représentent chacun un groupe alkyle en C₁₋₆.
 7. Procédé selon la revendication 5, dans lequel l'un parmi R⁵ et R⁶ représente un atome d'hydrogène et l'autre représente un groupe chlorophényle ou trifluorométhylphényle, et R⁷ et R⁸ représentent chacun un groupe méthyle ou éthyle.
 8. Procédé selon la revendication 1, dans lequel ledit dérivé est la 2-(4-chlorophényl)-4-(diéthylamino)acétyl-3,4-dihydro-2H-1,4-benzothiazine ou l'un de ses sels acceptables du point de vue pharmaceutique.
 9. Procédé selon la revendication 1, dans lequel ledit dérivé est la 3-(4-chlorophényl)-1-(diéthylamino)acétyl-2,3-dihydro-1H-naphto[2,1-b][1,4]thiazine ou l'un de ses sels acceptables du point de vue pharmaceutique.


10. Procédé selon la revendication 1, dans lequel ledit dérivé est la 1-[3-diméthylamino)propyl]-3-(3-trifluorométhylphényl)-1H-naphto[2,1-b][1,4]thiazin-2(3H)-one ou l'un de ses sels acceptables du point de vue pharmaceutique.

11. Procédé de préparation d'un dérivé de thiazine ou d'oxazine de formule [1] suivante :



dans laquelle R¹ et R² représentent chacun un atome d'hydrogène ou forment un noyau naphthalène avec le noyau benzène ; R³ et R⁴ représentent chacun un atome d'hydrogène, ou bien l'un d'entre eux représente un atome d'halogène et l'autre représente un atome d'hydrogène ; X représente un atome de soufre ou un atome d'oxygène ; R⁵ et R⁶ sont identiques ou différents et représentent chacun i) un atome d'hydrogène, ii) un groupe alkyle en C₁₋₈, iii) un groupe cycloalkyle en C₃₋₈, iv) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un trihalogéno(alkyle en C₁₋₈), un groupe alkyle en C₁₋₈ et un groupe alcoxy en C₁₋₈, v) un groupe naphthyle, vi) un groupe alkyle qui porte comme substituant un groupe phényle ou un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₈), un groupe alkyle en C₁₋₈ et un groupe alcoxy en C₁₋₈, ou vii) un groupe monohétérocyclique contenant un atome de soufre ; l'un parmi Z¹ et Z² représente un atome d'oxygène et l'autre représente deux atomes d'hydrogène ; A représente un groupe alkylène en C₁₋₆ ; R⁷ et R⁸ sont identiques ou différents et représentent chacun i) un atome d'hydrogène, ii) un groupe alkyle en C₁₋₆, iii) un groupe alcényle en C₂₋₆, iv) un groupe alcynyle en C₂₋₆, ou v) un groupe alkyle en C₁₋₈ qui porte comme substituant un groupe phényle ou un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₈), un groupe alkyle en C₁₋₈ et un groupe alcoxy en C₁₋₈, ou forment ensemble avec l'atome d'azote adjacent un groupe monohétérocyclique contenant un atome d'azote ; à condition que lorsque R¹ et R² représentent chacun un atome d'hydrogène, Z² représente un atome d'oxygène et l'un parmi R⁵ et R⁶ représente un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(C₁₋₆), un groupe alkyle en C₁₋₈ et un groupe alcoxy en C₁₋₈, un groupe naphthyle ou un groupe monohétérocyclique contenant un atome de soufre, ou l'un de ses sels acceptable du point de vue pharmaceutique qui comprend les étapes consistant


(a) à faire réagir un composé de formule :



dans lequel R¹, R², R³, R⁴, R⁵, R⁶ et X et Z¹ sont tels que définis ci-dessus ou un sel de celui-ci avec un composé de formule :




dans laquelle Y¹ et Y² sont identiques ou différents et représentent chacun un résidu réactif, et A et Z² sont tels que définis ci-dessus, pour obtenir un composé de formule :



15 dans lequel R¹, R², R³, R⁴, R⁵, X, A, Z¹, Z² et Y¹ sont tels que définis ci-dessus, puis à faire réagir le composé [IV] ci-dessus avec un composé amine de formule :




25 dans laquelle R⁷ et R⁸ sont tels que définis ci-dessus ou avec l'un de ses sels, ou (b) à faire réagir le composé de formule [II] ou l'un de ses sels avec un composé de formule :



35 dans lequel Y³ représente un résidu réactif et Z², A, R⁷ et R⁸ sont tels que définis ci-dessus, ou (c) dans le cas où dans le composé [I] A représente un groupe éthylène, Z¹ représente deux atomes d'hydrogène, et Z² représente un atome d'oxygène, à faire réagir le composé de formule [II] ou l'un de ses sels avec un composé d'acide acrylique de formule :




dans lequel Y² est tel que défini ci-dessus, pour obtenir un composé de formule :



55 dans lequel R¹, R², R³, R⁴, R⁵, R⁶, et X sont tels que définis ci-dessus, puis à faire réagir ensuite le composé de formule [VIII] ci-dessus avec un composé amine [V], ou l'un de ses sels, ou (d) dans le cas où dans les composés [I] au moins l'un parmi R⁷ et R⁸ représente un groupe alkyle en C₁₋₆, un groupe alcényle en C₂₋₆, un groupe alcynyle en C₂₋₆, ou un groupe alkyle en C₁₋₆ qui porte comme substituant un groupe phényle ou un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène,

un groupe trihalogéno(alkyle en C₁₋₆), un groupe alkyle en C₁₋₆ et un groupe alcoxy en C₁₋₆, à faire réagir un composé de formule :




15 dans laquelle R¹, R², R³, R⁴, R⁵, R⁶, X, A, Z¹ et Z² sont tels que définis ci-dessus, et R⁷¹ représente un atome d'hydrogène, un groupe alkyle en C₁₋₆, un groupe alcényle en C₂₋₆, un groupe alcynyle en C₂₋₆, ou un groupe alkyle en C₁₋₆ portant comme substituant un groupe phényle ou un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆), un groupe alkyle en C₁₋₆ et un groupe alcoxy en C₁₋₆, ou l'un de ses sels avec un composé de formule :

R⁸¹.Y⁴

[XI]

20 dans lequel R⁸¹ représente un groupe alkyle en C₁₋₆, un groupe alcényle en C₂₋₆, un groupe alcynyle en C₂₋₆, ou un groupe alkyle en C₁₋₆ portant comme substituant un groupe phényle ou un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆), un groupe alkyle en C₁₋₆ et un groupe alcoxy en C₁₋₆, et Y⁴ représente un résidu réactif, éventuellement suivie par la conversion du composé [I] sous forme libre en l'un de ses sels acceptables du point de vue pharmaceutique.

- 25
- 30 12. Procédé tel que revendiqué dans la revendication 11, dans lequel le dérivé de formule [I] est produit en utilisant un composé de formule :



40 dans laquelle X' représente un atome de soufre ou un atome d'oxygène ; R⁵¹ et R⁶¹ sont identiques ou différents et représentent chacun i) un atome d'hydrogène, ii) un groupe alkyle en C₁₋₆, iii) un groupe cycloalkyle en C₃₋₆, iv) un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆), un groupe alkyle en C₁₋₆, et un groupe alcoxy en C₁₋₆, v) un groupe naphthyle, vi) un groupe alkyle en C₁₋₆ portant comme substituant un groupe phényle ou un groupe phényle portant un ou deux substituants choisis parmi un atome d'halogène, un groupe trihalogéno(alkyle en C₁₋₆), un groupe alkyle en C₁₋₆ et un groupe alcoxy en C₁₋₆, ou vii) un groupe monohétérocyclique contenant un atome de soufre ; Z¹¹ représente un atome d'oxygène ou représente deux atomes d'hydrogène ; à condition que lorsque Z¹¹ représente deux atomes d'hydrogène et R⁵¹ et R⁶¹ représentent chacun un atome d'hydrogène, X' représente un atome de soufre, ou l'un de ses sels.

- 45
- 50 13. Procédé de production d'une composition pharmaceutique, dans lequel on prépare un composé de formule [I] par le procédé de la revendication 11 ou de la revendication 12 et on mélange le composé résultant ou l'un de ses sels actifs du point de vue pharmaceutique avec un véhicule ou un diluant acceptable du point de vue pharmaceutique.
- 55 14. Procédé tel que revendiqué dans l'une quelconque des revendication précédentes, par lequel on produit un médicament destiné à la prophylaxie et au traitement d'encéphalopathie ischémique et/ou de dyscrasie des neurones cérébraux.